



PatBase Export

Created by: SIC9@patbase.com
Created on: 02 October 2024
Search: TAC=(MAT2A) and PRD=1950:2020

Records: 76 (1-76 of 76)
Export type: Family Export

1. Family 64062880 (US2018153975 AA)

[View in PatBase](#)

Title

[EN] SHARED NEOANTIGENS

Abstract

[EN] Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1 percent of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5 percent of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5 percent of the subjects in the population of subjects suffering from cancer.

International Class: A61K39/00; A61P35/00; A61K; A61K38/00; A61K45/06; A61K47/00; C07K14/47; C12Q1/6886; C07K16/24; A61K31/4439; A61K31/506; A61K31/517; A61K31/519; A61K31/5377; A61K39/39; A61K39/395; A61K45/00; A61P37/04; A61P43/00; A61K31/437; A61K31/4545; A61K38/08; A61K38/17; A61P35/02; A61P37/02; C07K14/82; A61K31/7088; A61K39/385; A61K47/42; C07K14/705; C12N15/12

Cooperative Patent Class: A61K2039/515; A61K2039/555; A61K2039/70; A61K2121/00; A61K2300/00; A61K38/00; A61K39/00; A61K39/0011; A61K39/001104; A61K39/001106; A61K39/001151; A61K39/001152; A61K39/001162; A61K39/001164; A61K39/001197; A61K45/06; A61K47/00; A61P35/00; A61P35/02; A61P35/04; C07K14/4748; C12N2320/31; C12N2320/34; C12Q1/6886; C12Q2600/158; G01N2800/56; G01N2800/60; G01N2800/7028; Y02A50/30

US Class: 1/1; 424/184.1

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2016264623 AA	20171207	AU20160264623	20160520
AU2016264623 BB	20220630	AU20160264623	20160520
AU2022241521 AA	20221201	AU20220241521	20220928
BR112017024797 A2	20180807	BR20171124797	20160520
CA2986235 AA	20171116	CA20162986235	20160520
CL2017002945 A1	20180427	CL20170002945	20171120
CL2023002421 A1	20240209	CL20230002421	20230816
CN108025048 A	20180511	CN201680042436	20160520
CN108025048 B	20221025	CN201680042436	20160520
CN116196401 A	20230602	CN202211239802	20160520
CO20170012835 A2	20180510	CO20170012835	20171213
CR20170584 A	20180320	CR20170000584	20160520
CR20200476 A	20201202	CR20200000476	20160520
CR20230191 A	20230706	CR20230000191	20160520
ECSP17084137 A	20180531	EC20170084137	20171220
EP3297660 A2	20180328	EP20160732018	20160520
HK1251148 A1	20190125	HK20180110507	20180815
HK1251148 B	20230616	HK20180110507	20180815
HK1252267 A1	20190524	HK20180111576	20180907
HK40095388 A1	20240202	HK20234083548	20231130
IL255769 A0	20180131	IL20160255769	20160520
IL255769 A1	20230501	IL20160255769	20160520
IL255769 B2	20230901	IL20160255769	20160520
IL294183 A1	20230601	IL20160294183	20160520
IL294183 AA	20220801	IL20160294183	20160520
IL294183 B2	20231001	IL20160294183	20160520



Patent Number	Publication Date	Application Number	Application Date
IL302102 AA	20230601	IL20160302102	20160520
IN201717042732 A	20180316	IN201717042732	20171129
IN202218044062 A	20240209	IN202218044062	20220801
IN489512 B	20231229	IN201717042732	20171129
JP2018522822 T2	20180816	JP20170560196T	20160520
JP2021176866 A2	20211111	JP20210114423	20160520
JP2023103405 A2	20230726	JP20230081513	20160520
JP6913032 B2	20210804	JP20170560196T	20160520
JP7282834 B2	20230529	JP20210114423	20160520
KR20180010229 A	20180130	KR20177036611	20160520
MX2017014700 A1	20180815	MX20170014700	20160520
MX2023005122 A1	20230713	MX20230005122	20171116
MX2024006806 A1	20240621	MX20240006806	20171116
MX414130 B	20240618	MX20170014700	20160520
MY190974 A	20220525	MY20170001689	20160520
PE06702018 A1	20180419	PE20170002446	20160520
PE20180670 A1	20180419	PE20170002446	20160520
PE20186702 A1	20180419	PE20170002446	20160520
PH2017502321 A	20180625	PH20170502321	20171215
RU2017144467 A	20190620	RU20170144467	20160520
RU2017144467 A3	20191120	RU20170144467	20160520
RU2020132040 A	20201012	RU20200132040	20160520
RU2020132040 A3	20240229	RU20200132040	20160520
RU2733754 C2	20201006	RU20170144467	20160520
RU2827496 C2	20240927	RU20200132040	20160520
SG10202302481U A1	20231031	SG20231002481	20160520
TW201808327 A	20180316	TW20160115840	20160520
TW202346325 A	20231201	TW20230105056	20160520
TWI806815 B	20230701	TW20160115840	20160520
US10835585 BB	20201117	US20160575328	20160520
US2018153975 AA	20180607	US20160575328	20160520
US2020368337 AA	20201126	US20200859252	20200427
WO16187508 A2	20161124	WO2016US33452	20160520
WO16187508 A3	20170112	WO2016US33452	20160520

Priority Numbers: US20150179877P [20150520]; US20160389377P [20160223]; WO2016US33452 [20160520]; AU20220241521 [20220928]; AU20160264623 [20160520]; CL20170002945 [20171120]; CN201680042436 [20160520]; IN201717042732 [20171129]; JP20170560196T [20160520]; JP20170560196 [20160520]; JP20210114423 [20210709]; JP20210114423 [20160520]; JP20230081513 [20230517]; MX20170014700 [20171116]; RU20170144467 [20160520]; RU20200132040 [20160520]; US20160575328 [20160520]; US20170575328 [20171117]; US20200859252 [20200427]

Probable Patent Assignee: DANA FARBER CANCER INST INC

Assignees: GENERAL HOSPITAL CORP; BROAD INST INC; DANA FARBER CANCER INST INC; MASSACHUSETTS GEN HOSPITAL; GENERAL HOSPITAL COPORATION; EDWARD F FRITSCH; NIR HACHOHEN; MICHAEL STEVEN ROONEY; SACHET ASHOK SHUKLA; CATHERINE J WU; PAVAN BACHIREDDY; JING SUN; TE BROD INST INK

Non Std Assignees: FRITSCH EDWARD F; ROONEY MICHAEL STEVEN; HACHOHEN NIR; WU CATHERINE J; BACHIREDDY PAVAN; SUN JING; SHUKLA SACHET ASHOK; 415 MAIN STREET; 450 BROOKLINE AVENUE; MA 02215; 55 FRUIT STREET; 415 MAIN STREET CAMBRIDGE MA 02142; UNITED STATES OF AMERICADANA FARBER CANCER INST INC; 450 BROOKLINE AVE BOSTON MA 02215; 55 FRUIT STREET BOSTON MA 02114; BROAD INSTITUTE INC THE; DANA FARBER CANCER INSTITUTE INC; TE BROD INSTITYUT INK; DANA FARBER KENSER INSTITYUT INK; TE DZHENERAL KHOSPITAL KORPOREJSHN

Inventors: FRITSCH EDWARD F; ROONEY MICHAEL STEVEN; HACHOHEN NIR; WU CATHERINE J; BACHIREDDY PAVAN; SUN JING; SHUKLA SACHET ASHOK; EDWARD F FRITSCH; NIR HACHOHEN; MICHAEL STEVEN ROONEY; SACHET ASHOK SHUKLA; CATHERINE J WU; PAVAN BACHIREDDY; JING SUN; SACHET ASHOK SHUMKLA; ROONEY MICHAEL S; SHUKLA

SACHET A; SUN JIN; BACHIREDDY PAVEN; ROONEY MICHAEL; FRITSCH EDWARD; SHUKLA SACHET; HOCOHEN NIR; FRITCH EDVARD F; KHAKOEN NIR; RUNI MAJKL STIVEN; SHUKLA SASHET ASHOK; U KETRIN DZH; BACHIREDDI PAVAN; SUN TSZIN

Non Std Inventors: MICHAEL STEVEN ROONEY M; EDWARD F FRITSCH E; NIR HACHOHEN N; SACHET ASHOK SHUKLA S; CATHERINE J WU C; PAVAN BACHIREDDY P; E; N; M; S; C; P

Agent(s): PHILLIPS ORMONDE FITZPATRICK; MBM INTELLECTUAL PROPERTY AGENCY; MBM INTELLECTUAL PROPERTY LAW LLP; ALESSANDRI AND COMPANIA LIMITADA; ALESSANDRI U0026 COMPANIA LIMITADA; JOSE ANDRES RINCON USCATEGUI; EVENSON JANE HARRIET; MATHYS AND SQUIRE LLP; KING AND WOOD MALLESONS IP LTD; HK PAT IP LTD; JUN HE LAW OFFICES; WEBB AND CO; ARTURO DAVID REYES LOMELIN; SOYUZPATENT OOO; SOYUZPATENT SB FELITSINOJ OOO; CANTAB IP PTE LTD; FOLEY HOAG LLP; FOLEY HOAG LLP; KOWALSKI THOMAS J ET AL; VEDDER PRICE PC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

2. Family 88932463 (WO21254529 A1)


[View in PatBase](#)

Title
[EN] BICYCLIC COMPOUND

Abstract
[EN] Provided are a compound represented by formula (I) or a pharmaceutically-acceptable salt thereof, a pharmaceutical composition, and a preparation therefor, and use as an MAT2A inhibitor.

International Class: A61K31/519; A61P35/00; A61P35/04; C07D471/04

Cooperative Patent Class: A61K31/519; A61P35/00; A61P35/04; C07D471/04



Family Information

Patent Number	Publication Date	Application Number	Application Date
CN116406271 A	20230707	CN202180060895	20210714
CN116406271 B	20240924	CN202180060895	20210714
WO21254529 A1	20211223	WO2021CN106347	20210714

Priority Numbers: CN202010676114 [20200714]; CN202110054406 [20210115]; CN202110174940 [20210209]; WO2021CN106347 [20210714]

Probable Patent Assignee: JIANGSU SIMCERE PHARMACEUTICAL CO LTD

Assignees: JIANGSU SIMCERE PHARMACEUTICAL CO LTD; JIANGSU SIMCERE PHARM CO LTD

Non Std Assignees: JIANGSU SIMCERE PHARMACEUTICAL CO

Inventors: LI ZHEN; TANG FENG; ZHAO CHUNYAN; CHEN PING; TANG RENHONG; REN JINSHENG

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

3. Family 87840448 (US2023235399 AA)


[View in PatBase](#)

Title
[EN] METHOD FOR DETECTING ATOPIC DERMATITIS

Abstract
[EN] Provided are a marker for detecting atopic dermatitis, and a method for detecting atopic dermatitis using the marker. The method for detecting atopic dermatitis in a test subject comprises a step of measuring an expression level of a gene or an expression product thereof contained in a biological sample collected from the test subject.

International Class: C12N15/12; C12Q1/6809; C12Q1/6813; G01N33/50; G01N33/53; C07K14/47; C12Q1/6883; G01N33/68; C12N15/11; C12Q1/686; C12Q1/6869; C12Q1/6851; C12Q1/6876; C12Q1/68; C12Q1/00

Cooperative Patent Class: C07K14/47; C12Q1/6883; C12Q2600/158; G01N2800/202; G01N2800/60; G01N33/6893



Family Information

Patent Number	Publication Date	Application Number	Application Date
CN115485390 A	20221216	CN202180032407	20210428
EP4144862 A1	20230308	EP20210795650	20210428
EP4144862 A4	20240904	EP20210795650	20210428
JP2021175381 A2	20211104	JP20200081473	20200501
JP2021175382 A2	20211104	JP20200081503	20200501
JP2021175958 A2	20211104	JP20200081470	20200501
JP2022082068 A2	20220601	JP20200193411	20201120
JP2023157965 A2	20231026	JP20230134734	20200501
JP2023159312 A2	20231031	JP20230134732	20200501
JP2023162292 A2	20231108	JP20230134733	20200501
JP7328950 B2	20230817	JP20200193411	20201120
US2023235399 AA	20230727	US20220922565	20210428
WO21221138 A1	20211104	WO2021JP17112	20210428

Priority Numbers: JP20200081470 [20200501]; JP20200081473 [20200501]; JP20200081503 [20200501]; JP20200193411 [20201120]; WO2021JP17112 [20210428]; JP20230134734 [20230822]; JP20230134732 [20230822]; JP20230134733 [20230822]

Probable Patent Assignee: KAO CORP

Assignees: KAO CORP

Inventors: FUKAGAWA SATOKO; SHIMA KYOKO; TAKADA NAOTO; INOUE TAKAYOSHI; ISHIKAWA JUNKO; KUWANO TETSUYA

Agent(s): VOSSIUS AND PARTNER PATENTANWAELTE RECHTSANWAELTE MBB; PATENT CORPORATE BODY ARUGA PATENT OFFICE

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

4. Family 79720721 (US2022144820 AA)

[View in PatBase](#)

Title

[EN] AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER

Abstract


[EN] The present disclosure provides for compounds according to Formula I and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.

International Class: A61K31/5025; A61P35/00; C07D471/04; C07D471/20; C07D487/04; A61K31/437; A61K45/06; C07D519/00; A61K31/506; A61K31/538; A61P1/02; A61P1/04; A61P1/16; A61P1/18; A61P11/00; A61P11/02; A61P11/04; A61P13/02; A61P13/08; A61P13/10; A61P13/12; A61P15/00; A61P17/00; A61P19/08; A61P21/00; A61P25/00; A61P25/02; A61P27/02; A61P27/16; A61P35/02; A61P43/00; A61K31/517; A61K31/695; C07F7/12; C07B59/00; A61K31/00; C07D471/00; C07D487/00; A61K; A61P; C07D

Cooperative Patent Class: A61K31/5025; A61P35/00; C07B2200/05; C07D471/04; C07D471/20; C07D487/04; C07D519/00; C07B59/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR117544 AA	20210811	AR2019P103903	20191227
AU2019416349 AA	20210715	AU20190416349	20191227
AU2019416349 BB	20230928	AU20190416349	20191227
BR112021012595 A2	20210908	BR20211112595	20191227
CA3124952 AA	20210624	CA20193124952	20191227
CL2021001721 A1	20220218	CL20210001721	20210625
CL66310 B	20230104	CL20210001721	20210625
CN113454085 A	20210928	CN201980092742	20191227
CN113454085 B	20240507	CN201980092742	20191227
CO20210009879 A2	20211029	CO20210009879	20210727
CR20210410 A	20211208	CR20210000410	20191227
DE602019025060 D1	20230223	DE201960025060T	20191227
DK3902803 T3	20230213	DK20190845796T	20191227
EA202191801 A1	20211109	EA20210091801	20191227
EP3902803 A1	20211103	EP20190845796	20191227
EP3902803 B1	20230201	EP20190845796	20191227
ES2942310 T3	20230531	ES20190845796T	20191227
FI3902803 T3	20230425	FI20190845796T	20191227
GE20237519 B	20230710	GE20190015703	20191227
HK40061678 A1	20220602	HK20226051156	20220404
HK40061678 B	20230825	HK20226051156	20220404
HK40062089 A1	20220610	HK20226050161	20220317
HR20230161 T1	20230428	HR20230000161	20191227
HU061834 T2	20230828	HU20190845796T	20191227
ID2022PID00546 A	20220124	ID2021P0005574	20191227
IL284326 A1	20240401	IL20190284326	20191227
IL284326 AA	20210831	IL20190284326	20191227
IL284326 B2	20240801	IL20190284326	20191227
IN202117033446 A	20211029	IN202117033446	20210726
IN481497 B	20231215	IN202117033446	20210726



Patent Number	Publication Date	Application Number	Application Date
JO20210172 A1	20230130	JO20210000172	20191227
JP2022516883 T2	20220303	JP20210538127T	20191227
JP2024015340 A2	20240201	JP20230208546	20191227
JP7418441 B2	20240119	JP20210538127T	20191227
KR20220051301 A	20220426	KR20217023828	20191227
LT3902803 T	20230425	LT20190068652T	20191227
MA54608 A	20220406	MA20190054608	20191227
MA54608 B1	20230228	MA20190054608	20191227
MD3902803 T2	20231031	MD2021E001082T	20191227
MK12832 T1	20230630	MK20230000080T	20230222
MX2021007829 A1	20211026	MX20210007829	20191227
MX408994 B	20231213	MX20210007829	20191227
PE20212090 A1	20211104	PE20210001086	20191227
PL3902803 T3	20230522	PL20190845796T	20191227
PT3902803 T	20230428	PT20190845796T	20191227
RS64135 B1	20230531	RS20230000240	20191227
RU2021121997 A	20230127	RU20210121997	20191227
RU2021121997 A3	20230525	RU20210121997	20191227
RU2809987 C2	20231220	RU20210121997	20191227
SA521422405 B1	20240428	SA20210422405	20210627
SG11202106637S A1	20210729	SG20211106637	20191227
SI3902803 T1	20230630	SI20190030515T	20191227
TR2023001676 T4	20230424	TR20230001676T	20191227
TW202039490 A	20201101	TW20190148216	20191227
TWI816962 B	20231001	TW20190148216	20191227
UA127525 C2	20230920	UA20210004321	20191227
US12077534 BB	20240903	US20210418442	20191227
US2022144820 AA	20220512	US20210418442	20191227
VN86045 A	20220525	VN20210004533	20191227
WO20139991 A1	20200702	WO2019US68652	20191227
ZA202104423 A	20231220	ZA20210004423	20210625

Priority Numbers: US20180785519P [20181227]; WO2019US68652 [20191227]; EP20190845796 [20191227]; JP20210538127T [20191227]; JP20210538127 [20191227]; JP20230208546 [20231211]; RU20210121997 [20191227]; US20190418442 [20191227]

Probable Patent Assignee: LES LABORATOIRES SERVIER

Assignees: AGIOS PHARMACEUTICALS INC; LES LABORATOIRES SERVIER SAS; LES LABORATOIRES SERVIER; SERVIER LAB; LAB SERVIER; LES LABORATOIRES SERVIER INDUSTRIE

Non Std Assignees: KONTEATIS ZENON D; LI MINGZONG; REZNIK SAMUEL K; SUI ZHIHUA; 50 RUE CARNOT 92284 SURESNES CEDEX; LES LABORATOIRES SERVIER

Inventors: SUI ZHIHUA; REZNIK SAMUEL K; LI MINGZONG; KONTEATIS ZENON D; ZENON D KONTEATIS; MINGZONG LI; SAMUEL K REZNIK; ZHIHUA SUI; KONTEATIS ZENON; REZNIK SAMUEL; LI MING ZONG

Non Std Inventors: KONTEATIS ZENON D Z; LI MINGZONG M; REZNIK SAMUEL K S; D ZENON KONTEATIS; K SAMUEL REZNIK

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; ESTUDIO CAREY LTDA; MUELLER BORE AND PARTNER PATENTANWALTE PARTG MBB; CARPMAELS AND RANSFORD LLP; MARIA ALICIA IZQUIERDO BLANCO; DEACONS; LIU SHEN AND ASSOCIATES; MAROLITA SETIATI; REINHOLD COHN AND PARTNERS; VICTORIA LILIANA MEJIA TREJO; EVROMARKPAT; FULYA SUEMERALP; BAKERHOSTETLER; BAKERHOSTETLER; CONG TY TNHH TAM NHIN VA LIEN DANH; VISION AND ASSOCIATES CO LTD; LUCCI JOSEPH ET AL; BAKER AND HOSTETLER LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; MA; MD; TN; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN;




IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI;
NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ;
VC; VN; ZA; ZM; ZW

5. Family 76077949 (US2021115045 AA)

[View in PatBase](#)

Title
[EN] HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER

Abstract
[EN] The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.



International Class: A61K31/4375; A61K31/498; A61K31/4985; A61K31/502; A61K31/519; A61P35/00; C07D471/20; A61K31/527; C07D471/04; C07D471/10; C07D519/00; C07D239/48; C07D487/04; C07F9/6561; A61P35/02; A61P43/00; A61K31/444; A61K31/4709; A61K31/506; A61K31/517; A61K31/538

Cooperative Patent Class: A61K31/519; A61K31/527; A61P35/00; C07D471/04; C07D471/10; C07D471/20; C07D519/00; A61K31/4375; A61K31/498; A61K31/4985; A61K31/502

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR115326 AA	20201223	AR2019P100845	20190329
AU2019243289 AA	20200924	AU20190243289	20190328
AU2019243289 BB	20230112	AU20190243289	20190328
BR112020020104 A2	20210126	BR20201120104	20190328
CA3094476 AA	20200918	CA20193094476	20190328
CN111936499 A	20201113	CN201980023557	20190328

Patent Number	Publication Date	Application Number	Application Date
CN111936499 B	20230919	CN201980023557	20190328
DE602019044887 D1	20240125	DE201960044887T	20190328
EA202092320 A1	20210309	EA20200092320	20190328
EP3774805 A1	20210217	EP20190744896	20190328
EP3774805 B1	20240110	EP20190744896	20190328
ES2973114 T3	20240618	ES20190744896T	20190328
HK40049450 A1	20211217	HK20216037093	20210817
HK40049450 B	20240823	HK20216037093	20210817
HU066282 T2	20240728	HU20190744896T	20190328
IL277665 A1	20230201	IL20190277665	20190328
IL277665 AA	20201130	IL20190277665	20190328
IL277665 B2	20230601	IL20190277665	20190328
IN202017043368 A	20210924	IN202017043368	20201006
IN463343 B	20231103	IN202017043368	20201006
JP2021519783 T2	20210812	JP20200552849T	20190328
JP2023101762 A2	20230721	JP20230090963	20190328
JP7350005 B2	20230925	JP20200552849T	20190328
KR20200138769 A	20201210	KR20207030741	20190328
MA52232 A	20210217	MA20190052232	20190328
MX2020010005 A1	20201014	MX20200010005	20190328
MX402219 B	20230428	MX20200010005	20190328
PH2020551507 A	20210913	PH20200551507	20200918
PL3774805 T3	20240506	PL20190744896T	20190328
SG11202009195W A1	20201029	SG20201109195	20190328
TW201946629 A	20191216	TW20190111265	20190329
TWI719437 B	20210221	TW20190111265	20190329
UA127059 C2	20230329	UA20200006905	20190328
US11524960 BB	20221213	US20200040614	20190328
US2021115045 AA	20210422	US20200040614	20190328
WO19191470 A1	20191003	WO2019US24645	20190328
WO19191470 A8	20191212	WO2019US24645	20190328

Priority Numbers: WO2018CN081328 [20180330]; WO2019US24645 [20190328]; EP20190744896 [20190328]; JP20200552849T [20190328]; JP20200552849 [20190328]; JP20230090963 [20230601]; US20190040614 [20190328]

Probable Patent Assignee: LES LABORATOIRES SERVIER

Assignees: AGIOS PHARMACEUTICALS INC; LES LABORATOIRES SERVIER; SERVIER LAB; KONTEATIS ZENON D; LI MINGZONG; LIU PENG; MEDEIROS MATTHEW; REZNIK SAMUEL K; SUI ZHIHUA; TRAVINS JEREMY M; ZHOU SHUBAO; MA GUANGNING; POPOVICI MULLER JANETA; LES LABORATOIRES SERVIER INDUSTRIE; LAB SERVIER; SERVIER PHARMACEUTICALS LLC

Non Std Assignees: PHARMARESOURCES SHANGHAI CO LTD

Inventors: MA GUANGNING; ZHOU SHUBAO; POPOVICI MULLER JANETA; TRAVINS JEREMY M; SUI ZHIHUA; REZNIK SAMUEL K; MEDEIROS MATTHEW; LIU PENG; LI MINGZONG; KONTEATIS ZENON D; ZENON D KONTEATIS; MINGZONG LI; PENG LIU; MATTHEW MEDEIROS; SAMUEL K REZNIK; ZHIHUA SUI; JEREMY M TRAVINS; JANETA POPOVICI MULLER; SHUBAO ZHOU; GUANGNING MA; LI MING ZONG; ZHOU SHU BAO; MA GUANG NING

Non Std Inventors: POPOVICI; MULLER JANETA

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; CARPMAELS AND RANSFORD LLP; MARIA ALICIA IZQUIERDO BLANCO; DEACONS; REINHOLD COHN AND PARTNERS; ROMAN SOTO TRUJANO; BAKERHOSTETLER; BAKERHOSTETLER; PERDOK MONIQUE M ET AL; LUCCI JOSEPH ET AL; BAKER AND HOSTETLER LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; KH; MA; MD; TN; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL;

IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

6. Family 84627198 (US2022395508 AA)

[View in PatBase](#)

Title
[EN] PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS

Abstract
[EN] This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided are pharmaceutical combination comprising a PRMT5 Inhibitor and a cellular activity modulator selected from an EGFR inhibitor, a KRAS inhibitor, a KRAS-G12C inhibitor, a MEK inhibitor, a Bcl-2 inhibitor, a SOS1 inhibitor, a PARP inhibitor, a RAF inhibitor, a ERK inhibitor, a CDK4/6 inhibitor, a MALT1 inhibitor, a BTK inhibitor, MAT2A inhibitor, a PI3K inhibitor, a AKT inhibitor, a FGFR inhibitor, a Type I PRMT inhibitor, a STING agonist, or an immune checkpoint inhibitor/modulator.

International Class: A61K31/4439; A61K31/454; A61K31/502; A61K31/5025; A61K31/506; A61K31/517; A61K31/519; A61K31/5377; A61K31/55; A61P35/00; A61K31/444; A61K31/496; A61K39/395; A61K45/06; A61K45/00; A61P35/02; A61P43/00; A61K; A61P

Cooperative Patent Class: A61K2300/00; A61K31/4439; A61K31/444; A61K31/454; A61K31/502; A61K31/5025; A61K31/506; A61K31/517; A61K31/519; A61K31/5377; A61K31/55; A61P35/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2020371295 AA	20220428	AU20200371295	20201022
BR112022007808 A2	20220705	BR20221107808	20201022
CA3156135 AA	20220325	CA20203156135	20201022
CL2022001007 A1	20221223	CL20220001007	20220421
CN114599361 A	20220607	CN202080073338	20201022
CN114599361 B	20240709	CN202080073338	20201022
CO20220005053 A2	20220429	CO20220005053	20220422
CR20220175 A	20220621	CR20220000175	20201022
ECSP22032209 A	20220531	EC20220032209	20220421
EP4048270 A1	20220831	EP20200803923	20201022
GE20247638 B	20240710	GE20200015955	20201022
ID202204135 A	20220822	ID2022P0005621	20201022
IL292229 AA	20220601	IL20200292229	20201022
IN202227027405 A	20220826	IN202227027405	20220512
JP2023504230 T2	20230202	JP20220524048T	20201022
KR20220086628 A	20220623	KR20227016800	20201022
MX2022004917 A1	20220804	MX20220004917	20201022
PE20221154 A1	20220718	PE20220000657	20201022
US2022395508 AA	20221215	US20220767270	20201022
VN90086 A	20221025	VN20220002986	20201022
WO21079302 A1	20210429	WO2020IB59921	20201022
ZA202203770 A	20221221	ZA20220003770	20220401

Priority Numbers: IN201921042899 [20191022]; WO2020IB59921 [20201022]; CL20220001007 [20220421]

Probable Patent Assignee: LUPIN LTD


Assignees: LUPIN LTD; INDIA LUBIN CO LTD

Non Std Assignees: BHONDE MANDAR RAMESH; PALLE VENKATA P; KAMBOJ RAJENDER KUMAR; INDIA LUBIN CO

Inventors: BHONDE MANDAR RAMESH; KAMBOJ RAJENDER KUMAR; PALLE VENKATA P; BHONDE MANDAR; PALLE VENKATA; KAMBOJ RAJENDER; MANDAR RAMESH BHONDE; VENKATA P PALLE; RAJENDER KUMAR KAMBOJ; BOND MATTHEW R; KAMBOJ RAJENDRA KUMAR

Non Std Inventors: PALLE

Agent(s): PHILLIPS ORMONDE FITZPATRICK; RICHES MCKENZIE AND HERBERT LLP; JORGE GARAY PEREZ; POTTER CLARKSON; KUSNO HADI; PYERNIK PATENT ATTORNEYS; JORGE MIER Y CONCHA SEGURA; CONG TY TNHH TAM NHIN



VA LIEN DANH; VISION AND ASSOCIATES CO LTD; MAJUMDAR SUBHATOSH ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

7. Family 85989871 (WO21139775 A1)

[View in PatBase](#)

Title
[EN] PYRIDONE COMPOUND AND APPLICATION

Abstract
[EN] A compound as represented by general formula (A) or a pharmaceutically-acceptable salt thereof, a pharmaceutical composition and a preparation method therefor, and use thereof as an MAT2A inhibitor.

International Class: A61K31/519; A61P35/00; C07D471/04
Cooperative Patent Class: A61K31/519; A61P35/00; C07D471/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN114901664 A	20220812	CN202180007672	20210108
CN114901664 B	20240702	CN202180007672	20210108
WO21139775 A1	20210715	WO2021CN070887	20210108

Priority Numbers: CN202010026786 [20200110]; CN202010362378 [20200430]; CN202010658579 [20200709]; CN202010871227 [20200826]; CN202010958603 [20200914]; WO2021CN070887 [20210108]


Probable Patent Assignee: JIANGSU SIMCERE PHARM CO LTD

Assignees: JIANGSU SIMCERE PHARM CO LTD

Non Std Assignees: JIANGSU SIMCERE PHARMACEUTICAL CO; JIANGSU SIMCERE PHARMACEUTICAL CO LTD

Inventors: LI ZHEN; TANG FENG; ZHAO CHUNYAN; CHEN PING; ZHANG GUOBAO; TANG RENHONG; REN JINSHENG

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



8. Family 88794818 (US2024208965 AA)



[View in PatBase](#)

Title

[EN] HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Abstract

[EN] Disclosed herein are certain heteroaryl alkylene substituted 2-oxoquinazoline derivatives of Formula (I): (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.



International Class: A61K31/519; A61P35/02; C07D403/06; C07D403/14; C07D413/06; C07D417/06; C07D471/04; A61K31/517

Cooperative Patent Class: A61K31/517; A61K31/519; A61P35/02; C07D403/06; C07D403/14; C07D413/06; C07D417/06; C07D471/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP4165035 A1	20230419	EP20210736891	20210609
US2024208965 AA	20240627	US20230009172	20210609
WO21252678 A1	20211216	WO2021US36678	20210609

Priority Numbers: US20200037106P [20200610]; WO2021US36678 [20210609]; US20210009172 [20210609]

Probable Patent Assignee: IDEAYA BIOSCIENCES INC

Assignees: IDEAYA BIOSCIENCES INC; KNOX JOHN E

Inventors: KNOX JOHN E; CLEARY LEAH; FLEURY MELISSA; PEI ZHONGHUA

Agent(s): EISENFUEHR SPEISER; DOLAN GREGORY F ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

9. Family 86815261 (US2024182975 AA)

[View in PatBase](#)

Title

[EN] METHOD FOR SELECTING NORMALIZING GENES FOR COPY NUMBER VARIATION DETECTION AND COMPOSITION FOR DETECTING C-MET COPY NUMBER VARIATION SELECTED BY METHOD

Abstract

[EN] The present invention relates to a primer and probe set composition for CNV detection of a c-Met gene, and a kit comprising the same. By using the primer and probe set composition for CNV detection according to the present invention, it is possible to predict a prognosis of a c-Met-expressing cancer patient or a risk of mutation occurrence and to provide information required for targeted therapy of cancer, so as to be effectively used to provide clues for future treatment directions, as well as to determine a need to administer an anticancer drug, and to monitor the metastasis or recurrence of cancer.

International Class: C12Q1/6876; C12Q1/6886

Cooperative Patent Class: C12Q1/6876; C12Q1/6886; C12Q2563/107; C12Q2600/118; C12Q2600/156; C12Q2600/158

Family Information

Patent Number	Publication Date	Application Number	Application Date
KR20210107492 A	20210901	KR20200022590	20200224
KR20240087622 A	20240619	KR20240066096	20240521
US2024182975 AA	20240606	US20220801979	20210224
WO21172856 A1	20210902	WO2021KR02291	20210224

Priority Numbers: KR20200022590 [20200224]; KR20240066096 [20240521]; WO2021KR02291 [20210224]

Probable Patent Assignee: LOGONE BIO CONVERGENCE RES FOUNDATION


Assignees: LOGONE BIO CONVERGENCE RES FOUNDATION; ABION INC

Non Std Assignees: LOGONE BIO CONVERGENCE RESEARCH FOUNDATION; AVION CO LTD; JAE ROKWON BIO CONVERGENCE RESEARCH FOUNDATION

Inventors: KIM SUNG SU; JUNG YUN JUNG; CHOI JUN YOUNG; PARK KYUNG EUI; NAM JI HYE; KIM HA EUN

Agent(s): LEE HEE SOOK

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



10. Family 75130703 (US2021002296 AA)

[View in PatBase](#)

Title
[EN] PROTEIN DEGRADERS AND USES THEREOF

Abstract
[EN] The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

International Class: C07D211/88; C07D401/14; A61K31/519; A61P35/00; C07D401/12; C07D417/12; C07D417/14; C07D487/04; C07D495/04; C07D495/14

Cooperative Patent Class: A61P35/00; C07D401/12; C07D417/12; C07D417/14; C07D487/04; C07D495/04; C07D495/14

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3737666 A1	20201118	EP20190738560	20190114
EP3737666 A4	20220105	EP20190738560	20190114
HK40041597 A1	20210820	HK20216030143	20210429
US11485743 BB	20221101	US20200961366	20190114
US12006329 BB	20240611	US20220890847	20220818
US2021002296 AA	20210107	US20200961366	20190114
US2023295180 AA	20230921	US20220890847	20220818
WO19140380 A1	20190718	WO2019US13481	20190114

Priority Numbers: US20180616665P [20180112]; WO2019US13481 [20190114]; US20190961366 [20190114]; US20220890847 [20220818]; US20200961366 [20200710]

Probable Patent Assignee: KYMERA THERAPEUTICS INC

Assignees: KYMERA THERAPEUTICS INC

Inventors: MAINOLFI NELLO; JI NAN; KLUGE ARTHUR F

Agent(s): TOSTMANN HOLGER CARL; WALLINGER RICKER SCHLOTTER TOSTMANN PATENT U RECHTSANWAELTE PARTNERS; MARKS AND CLERK; DECHERT LLP; DECHERT LLP; MACKLIN TODD K; REID ANDREA L C; STEVENS MATTHEW C; REID ANDREA LC ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

11. Family 74606551 (US2021285952 AA)

[View in PatBase](#)

Title

[EN] NANOPARTICLES AND DISTINCT EXOSOME SUBSETS FOR DETECTION AND TREATMENT OF CANCER

Abstract

[EN] The present invention is directed to methods of diagnosing, prognosing, and managing treatment of cancer in a subject. These methods involve selecting a subject having cancer and obtaining, from the selected subject a population of either exomeres having a diameter less than 50 nm, small exosomes having a diameter of 60-80 nm, or large exosomes having a diameter of 90-120 nm. The exomeres, small exosomes, or large exosomes are recovered from the sample, and the exomeres, small exosomes, or large exosomes or portions thereof are contacted with one or more reagents suitable to detect: (1) higher or lower levels, relative to a standard for subjects not having cancer, or the presence or absence, of one or more proteins contained in said exomeres, small exosomes, or large exosomes, (2) higher or lower levels, relative to a standard for subjects not having cancer, or the presence or absence, of one or more N-glycans contained in said exomeres, small exosomes, or large exosomes, (3) higher or lower levels, relative to a standard for subjects not having cancer, or the presence or absence, of one or more lipids contained in said exomeres, small exosomes, or large exosomes, (4) the presence or absence of one or more genetic mutations in nucleic acid molecules associated with cancer and contained in said exomeres, small exosomes, or large exosomes, or (5) combinations thereof. Cancer is then diagnosed, prognosed, or treatment is modified based on this information.

International Class: C12Q1/6886; G01N33/574; G01N33/68; A61K31/713; A61K39/395; C12Q1/68

Cooperative Patent Class: C12Q1/6886; C12Q2600/106; C12Q2600/118; G01N33/574; G01N33/57484; G01N33/68; G01N33/6893

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN111971560 A	20201120	CN201880088472	20181203
CN111971560 B	20240611	CN201880088472	20181203
EP3716986 A1	20201007	EP20180882781	20181203
EP3716986 A4	20220209	EP20180882781	20181203
US2021285952 AA	20210916	US20200873700	20181203
US2023266329 AA	20230824	US20220082368	20221215
WO19109077 A1	20190606	WO2018US63612	20181203

Priority Numbers: US20170593504P [20171201]; US20180623992P [20180130]; WO2018US63612 [20181203]; US20180873700 [20181203]; US20200873700 [20200601]; US20220082368 [20221215]


Probable Patent Assignee: UNIV CORNELL

Assignees: UNIV CORNELL; CORNELL UNIV

Inventors: LYDEN DAVID; ZHANG HAIYING; LYDEN DAVID C

Agent(s): ADAMSON JONES; GOLDMAN MICHAEL L ET AL; LECLAIRRYAN PLLC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



12. Family 36070688 (US2009061454 AA)

[View in PatBase](#)

Title

[EN] DIAGNOSTIC AND PROGNOSTIC METHODS FOR LUNG DISORDERS USING GENE EXPRESSION PROFILES FROM NOSE EPITHELIAL CELLS

Abstract

[EN] The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer.

International Class: C12Q1/68; G01N33/574; C12N15/09; G01N33/50; C12Q1/6886; C40B30/04

Cooperative Patent Class: C12Q1/6886; C12Q2600/158; G01N33/57423

US Class: 1/1; 435/6; 435/6.14; 435/6.140P; 506/9; 506/9P

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2007223788 AA	20070913	AU20070223788	20070308
AU2007223788 BB	20121129	AU20070223788	20070308
CA2645310 AA	20081007	CA20072645310	20070308
EP1999472 A2	20081210	EP20070752688	20070308
EP2605018 A1	20130619	EP20120170635	20070308
JP2009529329 T2	20090820	JP20080558410T	20070308
JP2013126427 A2	20130627	JP20130063949	20130326
US11977076 BB	20240507	US20190579798	20190923
US2009061454 AA	20090305	US20070282320	20070308
US2011217717 AA	20110908	US20100940840	20101105
US2012190567 AA	20120726	US20110323655	20111212
US2017328908 AA	20171116	US20150690182	20150417
US2020096513 AA	20200326	US20190579798	20190923
WO07103541 A2	20070913	WO2007US06006	20070308
WO07103541 A3	20080110	WO2007US06006	20070308

Priority Numbers: US20060780552P [20060309]; WO2007US06006 [20070308]; EP20070752688 [20070308]; JP20080558410 [20070308]; JP20080558410T [20070308]; US20150690182 [20150417]; US20110323655 [20111212]; US20100940840 [20101105]; US20080282320 [20080909]; US20190579798 [20190923]; US20070282320 [20070308]

Probable Patent Assignee: TRUSTEES OF BOSTON UNIV

Assignees: UNIV BOSTON; TRUSTEES OF BOSTON UNIV; BERMAN JEFFREY S; BRODY JEROME S; SPIRA AVRUM; O REGAN ANTHONY W; TRUSTEES OF THE BOSTON UNIVERSITY


Non Std Assignees: THE TRUSTEES OF BOSTON UNIVERSITY; THE TRUSTEES OF THE BOSTON UNIVERSITY; GALA THERAPEUTICS BVBA SPRL; MADRYN HEALTH PARTNERS LP; VERACYTE INC; VISIUM HEALTHCARE PARTNERS LP; O'REGAN ANTHONY W

Inventors: BERMAN JEFFREY S; BRODY JEROME S; SPIRA AVRUM; O REGAN ANTHONY W; BRODY JEROME; O REGAN ANTHONY; BERMAN JEFFREY

Non Std Inventors: ANTHONY W O REGAN; AVRUM SPIRA; JEROME S BRODY; JEFFREY S BERMAN; O'REGAN ANTHONY W

Agent(s): SHELSTON IP; SHELSTON IP PTY LTD; SPRUSON AND FERGUSON; SMART AND BIGGAR; MUIR JUSTINE CLAIRE; BIOSCIENCE PATENTS LTD; BRYAN ESQ ERIN E; MORSE BARNES BROWN AND PENDLETON PC; MORSE BARNES BROWN AND PENDLETON PC; WARREN ESQ LISA M; MORSE BARNES BROWN AND PENDLETON PC ATTN IP MANAGER

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; HR; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY;




MA; MD; MG; MK; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RS; RU; SC; SD; SG; SL; SM; SN; SV;
SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

13. Family 68804885 (US2018079753 AA)

[View in PatBase](#)

Title
[EN] INHIBITORS OF CELLULAR METABOLIC PROCESSES

Abstract
[EN] The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA):



wherein R^A, R^B, R^C, R^D, and R^E are defined herein.

International Class: A61K31/407; A61K31/437; A61K31/522; A61P35/00; C07D471/04; C07D487/04; A61K31/519; C07F9/141; C07D231/00; C07D239/00; C07D239/42; C07D; C07D519/00; C07F9/6561; A61K31/53; A61K31/538; A61K31/675; A61P35/02; A61P43/00; C07B61/00; C07D401/04

Cooperative Patent Class: A61P35/00; C07D487/04; C07D519/00; A61K31/519; A61P35/02; A61P43/00; C07F9/141; C07F9/6561

US Class: 1/1; 514/80

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR109495 AA	20181212	AR2017P102433	20170831
AU2017319500 AA	20190411	AU20170319500	20170830
AU2017319500 BB	20200827	AU20170319500	20170830
AU2017319500 CA	20221020	AU20170319500	20170830
AU2020277158 AA	20201224	AU20200277158	20201125
BR112019003914 A2	20190528	BR20191103914	20170830
CA3034705 AA	20190221	CA20173034705	20170830
CA3034705 C	20210803	CA20173034705	20170830
CL2019000511 A1	20190517	CL20190000511	20190226
CL65776 B	20221027	CL20190000511	20190226
CN109890822 A	20190614	CN201780066270	20170830
CN109890822 B	20220830	CN201780066270	20170830
CO20190002237 A2	20190731	CO20190002237	20190311
CR20190157 A	20190813	CR20190000157	20170830
EA201990556 A1	20190930	EA20190090556	20170830
EP3507290 A1	20190710	EP20170764997	20170830
HK40011712 A1	20200717	HK20206001192	20200109
ID201907560 A	20191018	ID2019PID02432	20170830
ID82550 B	20220816	ID2019PID02432	20170830
IL265115 A0	20190430	IL20170265115	20170830
IL265115 A1	20220701	IL20170265115	20170830

Patent Number	Publication Date	Application Number	Application Date
IN201917010533 A	20190621	IN201917010533	20190318
IN470208 B	20231124	IN201917010533	20190318
JP2019529529 T2	20191017	JP20190531597T	20170830
JP2021073269 A2	20210513	JP20210014131	20170830
JP6832430 B2	20210224	JP20190531597T	20170830
KR102411150 B1	20220621	KR20197009218	20170830
KR20190046921 A	20190507	KR20197009218	20170830
MA46092 A	20210421	MA20170046092	20170830
MX2019002303 A1	20190715	MX20190002303	20170830
MX390277 B	20220224	MX20190002303	20170830
NI201900019 A	20190429	NI20190000019	20190226
NZ751515 A	20210226	NZ20170751515	20170830
PE20190761 A1	20190605	PE20190000437	20170830
PH2019500368 A	20191021	PH20190500368	20190221
SG11201901747V A1	20190328	SG20191101747	20170830
TH1901001065 A	20230529	TH20191001065	20170830
TW201811797 A	20180401	TW20170129811	20170831
TWI762505 B	20220501	TW20170129811	20170831
UA125852 C2	20220622	UA20190002825	20170830
US10329298 BB	20190625	US20170691408	20170830
US10800782 BB	20201013	US20180219735	20181213
US11325914 BA	20220510	US20200000411	20200824
US2018079753 AA	20180322	US20170691408	20170830
US2019233424 AA	20190801	US20180219735	20181213
USRE49934 E	20240423	US20220689209	20220308
VN10039117 B	20240325	VN20190001593	20170830
WO18039972 A1	20180308	WO2016CN097524	20160831
WO18045071 A1	20180308	WO2017US49439	20170830

Priority Numbers: WO2016CN097524 [20160831]; WO2016CN97524 [20160831]; US20170548738P [20170822]; WO2017US49439 [20170830]; AU20200277158 [20201125]; AU20170319500 [20170830]; JP20190531597T [20170830]; JP20210014131 [20210201]; US20180548738P [20180622]; US20170691408 [20170830]; US20180219735 [20181213]; US20200000411 [20200824]; US20220689209 [20220308]

Probable Patent Assignee: SERVIER PHARMACEUTICALS LLC

Assignees: AGIOS PHARMACEUTICALS INC; LES LABORATOIRES SERVIER; SERVIER LAB; KONTEATIS ZENON D; SUI ZHIHUA; TRAVINS JEREMY M; YE ZHIXIONG; ZENON D KONTEATIS; ZHIHUA SUI; JEREMY M TRAVINS; ZHIXIONG YE; SERVIER PHARMACEUTICALS LLC; AGIOS PHARMACEUTICAL INC; AGOS PHARMACEUTCALS INC

Non Std Assignees: LES LABORATOIRES SERVIER SAS; VIVA BIOTECH SHANGHAI LTD

Inventors: KONTEATIS ZENON D; YE ZHIXIONG; SUI ZHIHUA; TRAVINS JEREMY M; ZENON D KONTEATIS; ZHIHUA SUI; JEREMY M TRAVINS; ZHIXIONG YE; YE ZHXONG; KONTEATS ZENON D; SU ZHHUA; TRAVNS JEREMY M

Non Std Inventors: KONTEATIS; TRAVINS; M TRAVINS JEREMY M; D KONTEATIS ZENON D

Agent(s): FB RICE PTY LTD; BLAKE CASSELS AND GRAYDON LLP; ESTUDIO TRANSGLOBO LTDA; PLOUGMANN VINGTOFT A S; DEACONS; GEORGE WIDJOJO; GEORGE WIDJOJO SH; GE EHRlich 1995 LTD; HECTOR PATRICIO VALDES KING; SCHWEGMAN LUNDBERG AND WOESSNER PA; SCHWEGMAN LUNDBERG AND WOESSNER PA; BAKERHOSTETLER; BAKERHOSTETLER; CONG TY CO PHAN TU VAN TRUNG THUC; TRUNG THUC JSC; NTD PATENT AND TRADEMARK AGENCY LTD; BLACK DAVID W ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

14. Family 86581320 (US2023080158 AA)

[View in PatBase](#)

Title
[EN] SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME

Abstract
[EN] The present invention relates to a specific set of circulating biomarkers and related methods and kits for the diagnosis of Brugada Syndrome in a human being.

International Class: C12Q1/6883; G01N33/68; G01N33/92; C12Q1/02; C12Q1/6813; C12Q1/6837; C12Q1/6844; C12Q1/6851; C12Q1/686; C12Q1/6874; G01N33/50; G01N33/52; G01N33/53; G16H10/40

Cooperative Patent Class: C12Q1/686; C12Q1/6883; C12Q2600/158; G01N2800/32; G01N2800/326; G01N33/6812; G01N33/6893; G01N33/92; G16H10/40

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2021220003 AA	20220908	AU20210220003	20210211
BR112022015999 A2	20221011	BR20221115999	20210211
CA3166598 AA	20220729	CA20213166598	20210211
CN115485393 A	20221216	CN202180014235	20210211
DE602020028164 D1	20240418	DE202060028164T	20200214
EP3865591 A1	20210818	EP20200157309	20200214
EP3865591 B1	20240403	EP20200157309	20200214
EP3865591 C0	20240403	EP20200157309	20200214
IL295171 AA	20220901	IL20210295171	20210211
JP2023514292 T2	20230405	JP20220549367T	20210211
KR20220140533 A	20221018	KR20227029326	20210211
MX2022009975 A1	20221107	MX20220009975	20210211
TW202140800 A	20211101	TW20210104204	20210204
US2023080158 AA	20230316	US20220799400	20210211
WO21161208 A1	20210819	WO20211B51121	20210211

Priority Numbers: EP20200157309 [20200214]; WO20211B51121 [20210211]

Probable Patent Assignee: CARDIOMIX S R L

Assignees: CARDIOMIX S R L; PAPPONE CARLO; ANASTASIA LUIGI; CICONTE GIUSEPPE; VICEDOMINI GABRIELE; CARDIOMICS LLC


Non Std Assignees: CARDIOMIX SRL

Inventors: ANASTASIA LUIGI; PAPPONE CARLO; CICONTE GIUSEPPE; VICEDOMINI GABRIELE; CARLO PAPPONE; LUIGI ANASTASIA; GIUSEPPE CICONTE; GABRIELE VICEDOMINI; PAPONE CARLO; HIKENT GEORGE; VESEDOMINI GABRIELE

Non Std Inventors: GABRIELEVICEDOMINI

Agent(s): AJ PARK; ROBIC; ROBIC AGENCE PI SEC ROBIC IP AGENCY LP; CALOGERO IDA; PAULINA BEN AMI PATENT ATTORNEYS; MARIA ANGELICA PARDAVELL JUAREZ; DE GREGORI ANTONELLA ET AL

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW





15. Family 92200043 (US2024124454 AA)

[View in PatBase](#)

Title
[EN] TRICYCLIC COMPOUND AND USE THEREOF

Abstract
[EN] The compound as shown in formula (I) or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a preparation method therefor, and the use thereof as an MAT2A inhibitor. Ring A, ring Q, X, Y, X₁, X₂, L and R¹ in formula (I) are as defined in the description.



International Class: C07D519/00; A61K31/519; A61P35/00; C07D471/04; A61K31/4375; A61K31/444; A61K31/4738; A61K31/497; A61K31/506; A61P43/00; C07D471/14; C07D498/14; A61K31/437; A61K31/553; A61K31/554; C07D498/04; C07D513/14

Cooperative Patent Class: C07D471/04; C07D471/14; C07D498/04; C07D498/14; C07D513/14

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN116670144 A	20230829	CN202180088735	20211230
EP4273146 A1	20231108	EP20210914595	20211230
JP2024502097 T2	20240117	JP20230540755T	20211230
TW202227443 A	20220716	TW20210149597	20211230
US2024124454 AA	20240418	US20230260004	20211230
WO22143864 A1	20220707	WO2021CN142847	20211230

Priority Numbers: CN202011637193 [20201231]; CN202110213607 [20210226]; CN202110477136 [20210429]; CN202110780130 [20210709]; CN202110998242 [20210827]; WO2021CN142847 [20211230]

Probable Patent Assignee: NANJING ZAIMING PHARMACEUTICAL CO LTD

Assignees: NANJING ZAIMING PHARMACEUTICAL CO LTD; JIANGSU SIMCERE PHARMACEUTICAL CO LTD; JIANGSU SIMCERE PHARM CO LTD

Non Std Assignees: NANJING ZAIMING PHARMACEUTICAL CO; JIANGSU SIMCERE PHARMACEUTICAL CO

Inventors: LI ZHEN; TANG FENG; LIU LE; ZHAO CHUNYAN; CHEN PING; TANG RENHONG; REN JINSHENG; ZHAO CHUNYAN; TANG REN HONG; REN JIN SHENG

Agent(s): KRAUSS JAN; INSIGHT INTELLECTUAL PROPERTY LTD

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AP; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EA; EC; EG; EP; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OA; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

16. Family 77412302 (US2020022984 AA)

[View in PatBase](#)

Title
[EN] METHOD OF TREATING A METHIONINE-DEPENDENT CANCER

Abstract
[EN] The present specification relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.

International Class: A61K31/52; A61K31/67; A61K31/7105; A61P35/04; C12Q1/6886

Cooperative Patent Class: A61K31/52; A61K31/67; A61K31/7105; A61P35/04; C12Q1/6886; C12Q2600/106; C12Q2600/112; C12Q2600/158

Family Information

Patent Number	Publication Date	Application Number	Application Date
US11376256 BB	20220705	US20180039916	20180719
US11872230 BB	20240116	US20220745292	20220516
US2020022984 AA	20200123	US20180039916	20180719
US2022280520 AA	20220908	US20220745292	20220516

Priority Numbers: US20180039916 [20180719]; US20220745292 [20220516]


Probable Patent Assignee: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH

Assignees: AGENCY SCIENCE TECH AND RES; AGENCY FOR SCIENCE TECH AND RESEARCH

Non Std Assignees: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH

Inventors: WANG ZHENXUN; TAM WAI LEONG; YIP LIAN YEE; HO YING SWAN; WU ZHENGWEI; LIM BING

Agent(s): MCCARTER AND ENGLISH LLP; MCCARTER AND ENGLISH LLP; ZACHARAKIS MARIA LACCOTRIPE; YU MIAO



17. Family 91055424 (WO22078403 A1)

[View in PatBase](#)

Title
[EN] SUBSTITUTED PYRIDONE COMPOUND AND APPLICATION

Abstract
[EN] The present invention relates to a compound shown in general formula (A) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, a preparation method for the compound, and a use of the compound as an MAT2A inhibitor.

International Class: A61K31/519; A61P35/00; C07D471/04
Cooperative Patent Class: A61K31/519; A61P35/00; C07D471/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN116782903 A	20230919	CN202180070837	20211013
WO22078403 A1	20220421	WO2021CN123577	20211013

Priority Numbers: CN202011105645 [20201015]; CN202110182410 [20210210]; CN202110361446 [20210402]; WO2021CN123577 [20211013]


Probable Patent Assignee: NANJING ZAIMING PHARMACEUTICAL CO LTD

Assignees: NANJING ZAIMING PHARMACEUTICAL CO LTD; JIANGSU SIMCERE PHARM CO LTD

Non Std Assignees: NANJING ZAIMING PHARMACEUTICAL CO; JIANGSU SIMCERE PHARMACEUTICAL CO; JIANGSU SIMCERE PHARMACEUTICAL CO LTD

Inventors: LI ZHEN; TANG FENG; LIU LE; ZHAO CHUNYAN; CHEN PING; TANG RENHONG; REN JINSHENG

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



18. Family 71793301 (US2020202976 AA)

[View in PatBase](#)

Title

[EN] SYSTEMS-LEVEL ANALYSIS OF 32 TCGA CANCERS REVEALS DISEASE-DEPENDENT TRNA FRAGMENTATION PATTERNS AND VERY SELECTIVE ASSOCIATIONS WITH MESSENGER RNAS AND REPEAT ELEMENTS

Abstract

[EN] Methods of treating a disease by leveraging positive and negative correlations between tRNA-derived fragments (tRF) and messenger RNA (mRNA) wherein said correlations can be used to establish a level of granularity that is specific to a disease of interest wherein said disease-specific positive and negative correlations can allow a level of therapeutic intervention that will be unprecedented because it will have been informed by three dimensions: at least one mRNA of interest; at least one tRF that are positively/negatively correlated with it; and, the identity of the disease in which one wishes to modulate the abundance of the at least one mRNA of interest.

International Class: C12N15/113; C12Q1/68; G01N33/50; C12Q1/6886; G16B20/00; G16B30/00

Cooperative Patent Class: C12N15/11; C12Q1/6886; C12Q2600/112; C12Q2600/158; C12Q2600/178; G16B20/00; G16B30/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3628055 A1	20200401	EP20180794729	20180501
EP3628055 A4	20210609	EP20180794729	20180501
US11715549 BB	20230801	US20190609880	20180501
US2020202976 AA	20200625	US20190609880	20180501
US2023282308 AA	20230907	US20220082290	20221215
WO18204412 A1	20181108	WO2018US30525	20180501

Priority Numbers: US20170492662P [20170501]; WO2018US30525 [20180501]; US20180609880 [20180501]; US20190609880 [20191031]; US20220082290 [20221215]


Probable Patent Assignee: THOMAS JEFFERSON UNIV

Assignees: THOMAS JEFFERSON UNIV; UNIV JEFFERSON

Inventors: RIGOUTSOS ISIDORE; TELONIS ARISTEIDIS G

Agent(s): J A KEMP LLP; COZEN O CONNOR; COZEN O CONNOR; VOS STRACHE KYLE

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW




19. Family 89063938 (US2023219953 AA)

[View in PatBase](#)

Title
[EN] SULFONE DERIVATIVES

Abstract
[EN] The present invention provides compounds of formula I



wherein X^1 , X^2 , X^3 , X^4 , R^1 , R^{1a} , R^{1b} , $R^{2'}$, $R^{2?}$, $R^{3'}$, $R^{3?}$, R^6 and R^7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

International Class: A61K31/416; A61P35/00; C07D231/56; C07D487/04; A61K31/404; A61K31/437; A61K31/5025; C07D209/08; C07D405/12; C07D471/04; A61K; A61P; C07D

Cooperative Patent Class: A61K31/416; A61K31/437; A61K31/5025; A61P35/00; C07D209/08; C07D231/56; C07D405/12; C07D471/04; C07D487/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR122705 AA	20220928	AR2021P101714	20210622
AU2021294933 AA	20230202	AU20210294933	20210621
BR112022026105 A2	20230117	BR20221126105	20210621
CA3187145 AA	20221213	CA20213187145	20210621
CL2022003677 A1	20230728	CL20220003677	20221221
CN115916756 A	20230404	CN202180044141	20210621
CO20230000117 A2	20230427	CO20230000117	20230106
CR20220644 A	20230217	CR20220000644	20210621
EP4168392 A1	20230426	EP20210733139	20210621
HK40086621 A1	20230825	HK20236075737	20230710
ID202302066 A	20230228	ID2022P0015116	20210621
IL298824 AA	20230201	IL20210298824	20210621
IN202247073882 A	20230106	IN202247073882	20221220
JP2023531020 T2	20230720	JP20220578795T	20210621
KR20230026479 A	20230224	KR20237002321	20210621
MX2022016455 A1	20230201	MX20220016455	20210621

Patent Number	Publication Date	Application Number	Application Date
PE20230838 A1	20230519	PE20220002959	20210621
TW202208361 A	20220301	TW20210122555	20210621
TWI812966 B	20230821	TW20210122555	20210621
US2023219953 AA	20230713	US20220068360	20221219
VN96141 A	20230725	VN20220008357	20210621
WO21259831 A1	20211230	WO2021EP66767	20210621
ZA202213430 A	20230830	ZA20220013430	20221212

Priority Numbers: EP20200181363 [20200622]; WO2021EP66767 [20210621]; US20220068360 [20221219]

Probable Patent Assignee: HOFFMANN LA ROCHE INC

Assignees: HOFFMANN LA ROCHE; F HOFFMANN LA ROCHE AG; HOFFMANN LA ROCHE INC

Non Std Assignees: BELL ANDREW SIMON; BESNARD JEREMY; BRADLEY ANTHONY RICHARD; GREEN LUKE; HAAP WOLFGANG; KOCER BUELENT; KUGLSTATTER ANDREAS; LUCAS XAVIER; MATTEI PATRIZIO; MAZUNIN DMITRY; RIEMER CLAUS; VAN HOORN WILLEM PAUL; GRENZACHERSTRASSE 124 4070 BASEL; EXSCIENTIA LTD

Inventors: BELL ANDREW SIMON; BESNARD JRMY; BRADLEY ANTHONY RICHARD; GREEN LUKE; HAAP WOLFGANG; KOCER BUELENT; KUGLSTATTER ANDREAS; LUCAS XAVIER; MATTEI PATRIZIO; MAZUNIN DMITRY; RIEMER CLAUS; VAN HOORN WILLEM PAUL; BESNARD JEREMY; ANDREW SIMON BELL; JEREMY BESNARD; ANTHONY RICHARD BRADLEY; LUKE GREEN; WOLFGANG HAAP; BUELENT KOCER; XAVIER LUCAS; PATRIZIO MATTEI; DMITRY MAZUNIN; CLAUS RIEMER; WILLEM PAUL VAN HOORN; ANDREAS KUGLSTATTER; BESNARD JASON; BRADLEY ANTHONY R; COSER BULENT; KUGLESTATTER ANDREAS; MATHE PRATEEK; MAZUNIN DAVIDE; REMER CHRISTIAN; VAN HORN WILLEM P; BELL ANDREW; BRADLEY ANTHONY

Non Std Inventors: HAAP WOLF; GANG; ANDREASKUGLSTATTER; ANDREW SIMON BELL A S; JEREMY BESNARD J; ANTHONY RICHARD BRADLEY A R; LUKE GREEN L; WOLFGANG HAAP W; BUELENT KOCER B; ANDREAS KUGLSTATTER A; XAVIER LUCAS X; PATRIZIO MATTEI P; DMITRY MAZUNIN D; CLAUS RIEMER C; WILLEM PAUL VAN HOORN W P




Agent(s): GRIFFITH HACK; CAROLINA NAKATA; SMART AND BIGGAR LP; ESTUDIO CAREY LIMITADA; FRANCISCO CAREY CARVALLO; SCHIRLIN JULIEN; F HOFFMANN LA ROCHE AG; KING AND WOOD MALLESONS IP LTD; MAROLITA SETIATI; LUZZATTO AND LUZZATTO; ANDRES ALBERTO ESTEVA WURTS; CONG TY TNHH TAM NHIN VA LIEN DANH; VISION AND ASSOCIATES CO LTD; SCHIRLIN JULIEN ET AL ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

[View in PatBase](#)

[EN] AMIDOPYRIMIDONE DERIVATIVES

[EN] The present invention provides compounds of formula I or II:

 $\textcircled{\text{I}}$ 
$$(II)$$


International Class: A61K31/00; A61P35/00; C07D239/95; C07D401/12; C07D403/06; C07D403/12; C07D417/04; C07D471/04; C07D473/04; A61K31/517; A61K31/519; C07D401/04; C07D405/04; C07D487/04; C07D519/00; A61K31/506

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR122704 AA	20220928	AR2021P101713	20210622
AU2021295413 AA	20221201	AU20210295413	20210621
BR112022026080 A2	20230117	BR20221126080	20210621
CA3181790 AA	20221028	CA20213181790	20210621
CL2022003646 A1	20230804	CL20220003646	20221219
CN115867541 A	20230328	CN202180044144	20210621
CO20230000056 A2	20230327	CO20230000056	20230104
CR20220638 A	20230131	CR20220000638	20210621
EP4168394 A1	20230426	EP20210735633	20210621
HK40086586 A1	20230825	HK20236075343	20230703
ID202301730 A	20230220	ID2022P0014984	20210621
IL297879 AA	20230101	IL20210297879	20210621

Patent Number	Publication Date	Application Number	Application Date
IN202247073469 A	20230106	IN202247073469	20221219
JP2023531021 T2	20230720	JP20220578796T	20210621
KR20230027042 A	20230227	KR20227044191	20210621
MX2022015886 A1	20230124	MX20220015886	20210621
PE20230685 A1	20230421	PE20220002951	20210621
TW202216707 A	20220501	TW20210122553	20210621
US2023227449 AA	20230720	US20220068407	20221219
VN96142 A	20230725	VN20220008358	20210621
WO21259815 A1	20211230	WO2021EP66725	20210621

Priority Numbers: EP20200181341 [20200622]; WO2021EP66725 [20210621]; US20220068407 [20221219]

Probable Patent Assignee: HOFFMANN LA ROCHE INC

Assignees: HOFFMANN LA ROCHE; F HOFFMANN LA ROCHE AG; HOFFMANN LA ROCHE INC

Non Std Assignees: BELL ANDREW SIMON; BESNARD JEREMY; BRADLEY ANTHONY RICHARD; GREEN LUKE; HAAP WOLFGANG; KOCER BUELENT; KUGLSTATTER ANDREAS; LUCAS XAVIER; MATTEI PATRIZIO; MAZUNIN DMITRY; RATNI HASANE; RIEMER CLAUS; VAN HOORN WILLEM PAUL; GRENZACHERSTRASSE 124 4070 BASEL; EXSCIENTIA LTD

Inventors: BELL ANDREW SIMON; BESNARD JRMY; BRADLEY ANTHONY RICHARD; GREEN LUKE; HAAP WOLFGANG; KOCER BUELENT; KUGLSTATTER ANDREAS; LUCAS XAVIER; MATTEI PATRIZIO; MAZUNIN DMITRY; RATNI HASANE; RIEMER CLAUS; VAN HOORN WILLEM PAUL; BESNARD JEREMY; ANDREW SIMON BELL; JEREMY BESNARD; ANTHONY RICHARD BRADLEY; LUKE GREEN; WOLFGANG HAAP; BUELENT KOCER; XAVIER LUCAS; PATRIZIO MATTEI; DMITRY MAZUNIN; HASANE RATNI; CLAUS RIEMER; WILLEM PAUL VAN HOORN; ANDREAS KUGLSTATTER; BESNARD JEROME; BRADLEY ANDREW RICHARD; KUGLER STU TTER ANDREAS; MATT PATRICK; MARJUNIN DANIEL; REMER CHRISTOPHER; VAN HOORN WILLIAM P

Non Std Inventors: HAAP WOLF; GANG; ANDREASKUGLSTATTER; ANDREW SIMON BELL A S; JEREMY BESNARD J; ANTHONY RICHARD BRADLEY A R; LUKE GREEN L; WOLFGANG HAAP W; BUELENT KOCER B; ANDREAS KUGLSTATTER A; XAVIER LUCAS X; PATRIZIO MATTEI P; DMITRY MAZUNIN D; HASANE RATNI H; CLAUS RIEMER C; WILLEM PAUL VAN HOORN W P

Agent(s): GRIFFITH HACK; CAROLINA NAKATA; SMART AND BIGGAR LP; ESTUDIO CAREY LTDA; FRANCISCO CAREY CARVALLO; SCHIRLIN JULIEN; F HOFFMANN LA ROCHE AG; KING AND WOOD MALLESONS IP LTD; MAROLITA SETIATI; LUZZATTO AND LUZZATTO; ANDRES ALBERTO ESTEVA WURTS; CONG TY TNHH TAM NHIN VA LIEN DANH; VISION AND ASSOCIATES CO LTD



Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

21. Family 88794817 (US2023257377 AA)

[View in PatBase](#)

Title
[EN] 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Abstract
[EN] Disclosed herein are certain 2-aminoquinazoline derivatives of Formula (A) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.



International Class: A61K31/519; A61P35/00; C07D471/04; C07D487/04

Cooperative Patent Class: A61P35/00; C07D471/04; C07D487/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP4165040 A1	20230419	EP20210737276	20210609
US2023257377 AA	20230817	US20220009182	20210609
WO21252679 A1	20211216	WO2021US36679	20210609

Priority Numbers: US20200037109P [20200610]; WO2021US36679 [20210609]; US20210009182 [20210609]

Probable Patent Assignee: IDEAYA BIOSCIENCES INC

Assignees: IDEAYA BIOSCIENCES INC

Inventors: STEEL RICHARD; FLEURY MELISSA; BARSANTI PAUL A

Agent(s): EISENFUEHR SPEISER; DOLAN GREGORY F ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC



Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; KH; LI; LT; LU; LV; MA; MC; MD; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TN; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

22. Family 88794819 (US2023257359 AA)

[View in PatBase](#)

Title
[EN] 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Abstract
[EN] Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.



International Class: A61P35/00; C07D401/04; A61K31/517; C07D239/74; C07D239/78; C07D239/82; C07D471/04

Cooperative Patent Class: A61P35/00; C07D239/74; C07D239/78; C07D239/82; C07D401/04; C07D471/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2023257359 AA	20230817	US20220009194	20210609
WO21252680 A1	20211216	WO2021US36680	20210609

Priority Numbers: US20200037112P [20200610]; WO2021US36680 [20210609]; US20210009194 [20210609]

Probable Patent Assignee: IDEAYA BIOSCIENCES INC

Assignees: IDEAYA BIOSCIENCES INC

Inventors: CLEARY LEAH; FLEURY MELISSA; PEI ZHONGHUA; STEEL RICHARD

Agent(s): DOLAN GREOGRY F ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

23. Family 79469331 (US11046691 BA)


[View in PatBase](#)

Title

[EN] 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Abstract

[EN] Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA):



that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

International Class: A61K31/00; A61P35/00; C07D239/95; C07D401/12; C07D403/06; C07D403/12; C07D417/04; C07D471/04; C07D473/04; C07D487/04; C07D519/00; C12Q1/6886; A61K31/517; A61K31/519; A61K31/5377; A61P35/02; C07D239/80; C07D239/96; C07D401/02; C07D401/04; C07D401/14; C07D403/02; C07D403/04; C07D403/14; C07D405/02; C07D413/02; C07D413/12; C07D405/12; C07D417/12; C07D413/04

Cooperative Patent Class: A61K31/517; A61K31/519; A61K31/5377; A61P35/00; C07B2200/05; C07D239/80; C07D239/95; C07D239/96; C07D401/02; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/06; C07D403/12; C07D403/14; C07D405/12; C07D413/04; C07D413/12; C07D417/04; C07D417/12; C07D471/04; C07D473/04; C07D487/04; C07D519/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2019395338 AA	20210729	AU20190395338	20191209
BR112021010842 A2	20210824	BR20211110842	20191209
CA3121236 AA	20210525	CA20193121236	20191209
CL2021001508 A1	20220121	CL20210001508	20210609
CN113166078 A	20210723	CN201980081299	20191209
CO20210008895 A2	20210730	CO20210008895	20210706
EP3894396 A1	20211020	EP20190832505	20191209
HK40061246 A1	20220527	HK20226050520	20220323
IL283743 AA	20210729	IL20190283743	20191209
IN202117030075 A	20211210	IN202117030075	20210705
JP2022512156 T2	20220202	JP20210532487T	20191209
KR20210103498 A	20210823	KR20217021424	20191209
MA54452 A	20220316	MA20190054452	20191209
MX2021006841 A1	20210702	MX20210006841	20191209
PH2021551274 A	20211206	PH20210551274	20210531
RU2021119955 A	20230113	RU20210119955	20191209
RU2021119955 A3	20230531	RU20210119955	20191209
SG10202301591T A1	20230728	SG20231001591	20191209

Patent Number	Publication Date	Application Number	Application Date
SG11202105469Y A1	20210629	SG20211105469	20191209
TW202039487 A	20201101	TW20190145188	20191210
US11046691 BA	20210629	US20210175578	20210212
US11084798 BA	20210810	US20210175579	20210212
US11130759 BA	20210928	US20210175581	20210212
US2022106276 AA	20220407	US20210311873	20191209
VN81824 A	20211125	VN20210004116	20191209
WO20123395 A1	20200618	WO2019US65260	20191209

Priority Numbers: US20180777715P [20181210]; US20190835853P [20190418]; US20190883945P [20190807]; WO2019US65260 [20191209]; RU20210119955 [20191209]; US20210175578 [20210212]; US20210175579 [20210212]; US20210175581 [20210212]; US20190311873 [20191209]

Probable Patent Assignee: IDEAYA BIOSCIENCES INC

Assignees: IDEAYA BIOSCIENCES INC; IDEAYA BIOSCIENCE INC

Non Std Assignees: ALAM MUZAFFAR; CLEARY LEAH; FLEURY MELISSA; PEI ZHONGHUA; STEEL RICHARD; SUTTON JAMES; KNOX JOHN E; NEWBY ZACHARY E R; INTRABIO LTD

Inventors: SUTTON JAMES; STEEL RICHARD; PEI ZHONGHUA; CLEARY LEAH; KNOX JOHN E; FLEURY MELISSA; NEWBY ZACHARY E R; ALAM MUZAFFAR; JOHN E KNOX; ZACHARY E R NEWBY; KNOX JOHN; NEWBY ZACHARY; ALAM MOHAMMED

Non Std Inventors: MUZAFFAR ALAM; LEAH CLEARY; MELISSA FLEURY; ZHONGHUA PEI; RICHARD STEEL; JAMES SUTTON

Agent(s): PHILLIPS ORMONDE FITZPATRICK; GOWLING WLG CANADA LLP; CLARKE MODET U0026 CO CHILE SPA; EISENFUEHR SPEISER; MARKS AND CLERK; REINHOLD COHN AND PARTNERS; ROMAN SOTO TRUJANO; MARKS AND CLERK SINGAPORE LLP; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC; CONG TY CO PHAN TU VAN TRUNG THUC; TRUNG THUC JSC; DOLAN GREGORY F ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

24. Family 88794822 (US2023227409 AA)



[View in PatBase](#)

Title

[EN] QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Abstract

[EN] Disclosed herein are certain quinolinone derivatives of Formula (A) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.



International Class: C07D215/22; C07D215/227; C07D215/36; C07D215/38; C07D401/04; C07D417/12; C07D495/04; A61K31/4709; A61P35/00; C07D413/12

Cooperative Patent Class: A61P35/00; C07D215/22; C07D215/227; C07D215/36; C07D215/38; C07D401/04; C07D413/12; C07D417/12; C07D495/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2023227409 AA	20230720	US20220009206	20210609
WO21252681 A1	20211216	WO2021US36681	20210609

Priority Numbers: US20200037083P [20200610]; WO2021US36681 [20210609]; US20210009206 [20210609]

Probable Patent Assignee: IDEAYA BIOSCIENCES INC

Assignees: IDEAYA BIOSCIENCES INC

Inventors: CLEARY LEAH; FLEURY MELISSA; PEI ZHONGHUA

Agent(s): DOLAN GREGORY F ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

25. Family 82276213 (US2022251081 AA)




[View in PatBase](#)

Title

[EN] HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER

Abstract

[EN] The present disclosure provides for compounds according to Formula I, Formula II, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.



International Class: A61K31/4375; A61K31/519; A61P35/00; A61P35/02; C07D471/04; A61K31/522; C07D519/00; A61K31/444; A61K31/4985; A61K31/437; A61K45/06; C07D487/04; A61K45/00; A61P43/00

Cooperative Patent Class: A61P35/00; C07D471/04; C07D519/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR119046 AA	20211117	AR2020P101527	20200529
AU2020284018 AA	20220127	AU20200284018	20200529
BR112021023825 A2	20220208	BR20211123825	20200529
CA3142340 AA	20211130	CA20203142340	20200529
CO20210017981 A2	20220419	CO20210017981	20211228
CR20210670 A	20220211	CR20210000670	20200529
EP3976611 A1	20220406	EP20200760599	20200529
IL288395 AA	20220101	IL20200288395	20200529

Patent Number	Publication Date	Application Number	Application Date
IN202117061299 A	20220617	IN202117061299	20211228
JO20210317 A1	20230130	JO20210000317	20200529
JP2022534989 T2	20220804	JP20210570897T	20200529
MA56050 A	20220406	MA20200056050	20200529
PE20220387 A1	20220318	PE20210001990	20200529
RU2021139521 A	20230710	RU20210139521	20200529
SG11202112952S A1	20211230	SG20211112952	20200529
TW202110841 A	20210316	TW20200117971	20200529
US2022251081 AA	20220811	US20210615255	20200529
WO20243376 A1	20201203	WO2020US35036	20200529

Priority Numbers: US20190855395P [20190531]; WO2020US35036 [20200529]; US20200615255 [20200529]

Probable Patent Assignee: SERVIER LAB

Assignees: AGIOS PHARMACEUTICALS INC; LES LABORATOIRES SERVIER; SERVIER LAB

Non Std Assignees: KONTEATIS ZENON D; LI MINGZONG; REZNIK SAMUEL K; TRAVINS JEREMY M; SUI ZHIHUA

Inventors: KONTEATIS ZENON D; LI MINGZONG; REZNIK SAMUEL K; TRAVINS JEREMY M; SUI ZHIHUA; ZENON D KONTEATIS; SAMUEL K REZNIK; JEREMY M TRAVINS; KONTEATIS ZENON; REZNIK SAMUEL; TRAVINS JEREMY; LI MING ZONG

Non Std Inventors: MINGZONG LI; ZHIHUA SUI

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; CARPMAELS AND RANSFORD LLP; REINHOLD COHN AND PARTNERS; PALOVICH TRACY U ET AL; BAKER AND HOSTETLER LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

26. Family 87686764 (US2023193205 AA)

[View in PatBase](#)

Title
[EN] GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS

Abstract
[EN] Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment, fibroblasts are cultured in an acidic pH incubation medium before genetic modification, after genetic modification, or both. In another embodiment, fibroblasts are cultured under hypoxic conditions. In another embodiment, fibroblasts are treated with mitogenic factor-comprising composition(s) to increase the efficacy of genetic modification, wherein the mitogenic factor(s) may be cytokines, peptides, and/or proteins. In another embodiment, a therapeutically effective amount of the genetically modified fibroblasts are provided as a therapeutic application to an individual in need thereof. In another embodiment, the therapeutic application is treatment of fibrosis, treatment of inflammation, acceleration of healing, treatment of clotting disorders, or promotion of angiogenesis.

International Class: A61K35/33; C12N15/85; C12N5/077
Cooperative Patent Class: A61K35/33; C12N15/85; C12N2500/60; C12N2510/00; C12N2800/107; C12N5/0656

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2023193205 AA	20230622	US20220996109	20210419
WO21216460 A1	20211028	WO2021US27990	20210419

Priority Numbers: US20200012202P [20200419]; WO2021US27990 [20210419]; US20210996109 [20210419]


Probable Patent Assignee: FIGENE LLC

Assignees: FIGENE LLC

Inventors: ICHIM THOMAS; O HEERON PETE

Agent(s): MELISSA SISTRUNK; NORTON ROSE FULBRIGHT US LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



27. Family 90617359 (WO22063128 A1)


[View in PatBase](#)

Title

[EN] AROMATIC RING OR ARYLHETEROCYCLIC PYRIDONE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF

Abstract

[EN] An aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and a use thereof, in particular an aromatic ring or arylheterocyclic pyridone compound represented by formula (I), or pharmaceutically acceptable salts thereof, or enantiomers, diastereoisomers, tautomers, torsional isomers, solvates, polymorphs or prodrugs thereof, preparation methods therefor and a pharmaceutical use thereof. The compound has good MAT2a enzyme activity inhibition, and significantly inhibits the growth of multiple types of tumor cells, particularly tumor cells that are MTAP null.



International Class: A61K31/437; A61K31/4375; A61K31/47; A61K31/4709; A61P19/02; A61P29/00; A61P35/00; A61P37/02; A61P43/00; C07D215/54; C07D401/04; C07D401/12; C07D405/14; C07D471/04; C07D519/00

Cooperative Patent Class: A61K31/4375; A61P35/00; C07D471/04; C07D519/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN115960099 A	20230414	CN202111108358	20210922
WO22063128 A1	20220331	WO2021CN119638	20210922

Priority Numbers: CN202011018391 [20200924]; CN202011511127 [20201219]; CN202110027515 [20210110]; CN202110185507 [20210210]; CN202110363891 [20210402]

Probable Patent Assignee: SHANGHAI RINGENE BIOPHARMA CO LTD

Assignees: SHANGHAI RINGENE BIOPHARMA CO LTD

Non Std Assignees: SHANGHAI RINGENE BIOPHARMA CO

Inventors: WAN HUIXIN; WANG YAZHOU; MA JINGUI; ZHA CHUANTAO

Agent(s): SHANGHAI BESHINING LAW OFFICE

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

28. Family 90390402 (WO22052924 A1)


[View in PatBase](#)

Title

[EN] PREPARATION METHOD FOR CLASS OF NITROGEN-CONTAINING FUSED RING COMPOUNDS AND USE THEREOF

Abstract

[EN] A preparation method for a class of nitrogen-containing fused ring compounds and a use thereof, specifically, a nitrogen-containing fused ring compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsion isomer, solvate, polymorph or prodrug thereof, a preparation method therefor and a pharmaceutical application thereof, the definition of each group being as described in the description.



International Class: A61K31/4375; A61K31/444; A61K31/4985; A61K31/519; A61K31/5365; A61P1/00; A61P17/00; A61P17/06; A61P19/02; A61P21/04; A61P35/00; A61P35/02; A61P37/06; A61P5/00; A61P9/00; C07D471/04; C07D519/00

Cooperative Patent Class: A61K31/4375; A61K31/519; A61P35/00; C07D471/04; C07D519/00; Y02P20/55

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN115960098 A	20230414	CN202111053145	20210907
WO22052924 A1	20220317	WO2021CN117039	20210907

Priority Numbers: CN202010956278 [20200911]; CN202011174227 [20201028]; CN202011511129 [20201219]; CN202110027526 [20210110]; CN202110185489 [20210210]

Probable Patent Assignee: SHANGHAI RINGENE BIOPHARMA CO LTD

Assignees: SHANGHAI RINGENE BIOPHARMA CO LTD

Non Std Assignees: SHANGHAI RINGENE BIOPHARMA CO

Inventors: WAN HUIXIN; WANG YAZHOU; ZHA CHUANTAO; MA JINGUI

Agent(s): XU AND PARTNERS LLC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

29. Family 90390437 (WO22053022 A1)

[View in PatBase](#)

Title


[EN] METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Abstract

[EN] Compounds of formula (I) which may be used as a MAT2a inhibitor, pharmaceutical compositions comprising such compounds, the use of such compounds in the preparation of drugs for the treatment of cancer, and a preparation method for such compounds.

International Class: C07D471/04; A61K31/4375; A61K31/5377; A61K31/541; A61P35/00; A61K31/495; A61K31/4985; A61K31/519; C07D471/00

Cooperative Patent Class: A61K31/4375; A61K31/495; A61K31/4985; A61K31/519; A61P35/00; C07D471/00; C07D471/04



Family Information

Patent Number	Publication Date	Application Number	Application Date
CN115916778 A	20230404	CN202180047891	20210910
TW202214630 A	20220416	TW20210133783	20210910
WO22053022 A1	20220317	WO2021CN117734	20210910

Priority Numbers: CN202010957159 [20200912]; CN202011033800 [20200927]; CN202011151048 [20201024]; CN202011273346 [20201113]; CN202011480394 [20201215]; CN202110076170 [20210120]; CN202110184221 [20210208]; CN202110376023 [20210408]; WO2021CN117734 [20210910]

Probable Patent Assignee: SAINUOHABO PHARMACEUTICAL CHENGDU CO LTD

Assignees: SAINUOHABO PHARMACEUTICAL CHENGDU CO LTD; CHENGDU BRILLIANT PHARMACEUTICAL CO LTD; SCINNOHUB PHARMACEUTICAL CO LTD

Non Std Assignees: SAINUOHABO PHARMACEUTICAL CHENGDU CO; CHENGDU BRILLIANT PHARMACEUTICAL CO; SCINNOHUB PHARMACEUTICAL CO

Inventors: YANG ANLE; ZHANG DEWEI; DONG LIJIN; YI TAO; MENG JIANG; TIAN LIN; LIANG JIE; FENG ZE; LUO JUNJIE; HU KAI; LI PENG; ZHANG XIAODONG; ZHANG YI; HU XI; HOU YANAN; TANG JUN; ZHANG DE WEI; DONG LI JIN; LUO JUN JIE; ZHANG XIAO DONG; HOU YA NAN

Agent(s): ZHONGZI LAW OFFICE

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

30. Family 83005054 (US2023093080 AA)

[View in PatBase](#)

Title
[EN] PROTEIN DEGRADERS AND USES THEREOF

Abstract
[EN] The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

International Class: A61K47/54; A61K47/55; A61K31/403; A61K31/4035; C07D209/02; C07D209/44

Cooperative Patent Class: A61K47/545; A61K47/55; A61P25/00; A61P29/00; A61P35/00; A61P37/00; A61P5/00; C07D401/12; C07D495/14

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2023093080 AA	20230323	US20220597631	20200715
WO21011634 A1	20210121	WO2020US42109	20200715

Priority Numbers: US20190874225P [20190715]; US20190884972P [20190809]; US20190912999P [20191009]; US20200959316P [20200110]; WO2020US42109 [20200715]; US20200597631 [20200715]

Probable Patent Assignee: KYMERA THERAPEUTICS INC

Assignees: KYMERA THERAPEUTICS INC

Inventors: JI NAN; SINTCHAK MICHAEL D; ZHANG YI; ZHENG XIAOZHANG

Agent(s): REID ANDREA LC ET AL

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

31. Family 57465985 (US2016266140 AA)

[View in PatBase](#)

Title

[EN] BRUCELLOSIS, Q-FEVER, AND LYME DISEASE BIOMARKERS AND USES THEREOF

Abstract

[EN] The present invention provides biomarkers, methods and kits for diagnosing a Brucellosis, Q-Fever, and/or Lyme Disease, methods and kits for monitoring the effectiveness of treatment for Brucellosis, Q-Fever, or Lyme Disease, as well as methods for identifying a compound that can treat Brucellosis, Q-Fever, and/or Lyme Disease reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat a Brucellosis, Q-Fever, and/or Lyme Disease.

International Class: C40B30/00; C40B30/06; G01N33/48; G01N33/483; G01N33/53; G01N33/569; C40B; G01N; G01N33/573; G01N33/68

Cooperative Patent Class: G01N2333/23; G01N2560/00; G01N2570/00; G01N2800/26; G01N2800/52; G01N33/573; G01N33/6848; G01N33/6875; G01N33/6893; Y02A50/30

US Class: 1/1; 506/9

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2014233935 AA	20151001	AU20140233935	20140321
CA2907023 AA	20150915	CA20142907023	20140321
CA2907023 C	20230307	CA20142907023	20140321
DE602014058954 D1	20200116	DE201460058954T	20140321
EP2976638 A2	20160127	EP20140768036	20140321
EP2976638 A4	20170125	EP20140768036	20140321
EP2976638 B1	20191225	EP20140768036	20140321
HK1218575 A1	20170224	HK20160106535	20160607
US10191063 BB	20190129	US20150845399	20150904
US2016266140 AA	20160915	US20150845399	20150904
WO14147484 A2	20140925	WO2014IB00996	20140321
WO14147484 A3	20141211	WO2014IB00996	20140321

Priority Numbers: US20130803857P [20130321]; WO2014IB00996 [20140321]; EP20140768036 [20140321]; US20150845399 [20150904]

Probable Patent Assignee: CAPRION PROTEOMICS INC


Assignees: CAPRION PROTEOMICS INC

Non Std Assignees: PARAMITHIOTIS EUSTACHE; CROTEAU PASCAL

Inventors: CROTEAU PASCAL; PARAMITHIOTIS EUSTACHE

Agent(s): PIZZEYS PATENT AND TRADE MARK ATTORNEYS; PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; NORTON ROSE FULBRIGHT CANADA LLP SENCRL SRL; KRAUS AND WEISERT PATENTANWAELTE PARTGMBB; LADENDORF OLIVER; SPRUSON AND FERGUSON HONG KONG LTD; MCCARTER AND ENGLISH LLP; MCCARTER AND ENGLISH LLP; NAGLE DEBORAH L; SPARKS JONATHAN M; CONN DAVID L ET AL; BORDEN LADNER GERVAIS LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW




32. Family 91619334 (US2022169654 AA)

[View in PatBase](#)

Title
[EN] NEW ORGANIC COMPOUNDS

Abstract
[EN] The present application provides MAT2A inhibitor compounds that are useful as therapeutic agents. In some embodiments, the compounds are of Formula I, or pharmaceutically acceptable salts thereof:



wherein R¹, R², and X¹-X³ are defined herein.

International Class: A61K31/5025; A61P35/00; C07D487/04

Cooperative Patent Class: A61P35/00; C07D487/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR124136 AA	20230215	AR2021P103242	20211124
TW202237610 A	20221001	TW20210143846	20211124
US2022169654 AA	20220602	US20210534510	20211124
WO22115521 A1	20220602	WO2021US60709	20211124

Priority Numbers: US20200118252P [20201125]; US20210534510 [20211124]

Probable Patent Assignee: SERVIER PHARMACEUTICALS LLC

Assignees: SERVIER PHARMACEUTICALS LLC; SERVIER LAB

Non Std Assignees: LES LABORATOIRES SERVIER

Inventors: KONTEATIS ZENON D; LI MINGZONG; REZNIK SAMUEL K; SUI ZHIHUA; LI MING ZONG; REZNIK SAMUEL; KONTEATIS ZENON

Agent(s): LUCCI JOSEPH ET AL; BAKER AND HOSTETLER LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

33. Family 79720899 (US2022098203 AA)

[View in PatBase](#)

Title

[EN] AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER

Abstract

[EN] The present disclosure provides for compounds according to Formula I, Formula II, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.

International Class: A61K31/519; A61P35/00; C07D471/04; C07D471/20; C07D487/04; A61K31/437; A61K45/06; C07D519/00; A61K31/538; A61P35/02; A61K31/517; C07D403/04; C07D239/80

Cooperative Patent Class: A61K31/517; A61K31/519; A61P35/00; C07D239/80; C07D403/04; C07D471/04; C07D471/20; C07D487/04; C07D519/00

Family Information


Patent Number	Publication Date	Application Number	Application Date
AR115296 AA	20201216	AR2019P103901	20191227
AU2019414446 AA	20210715	AU20190414446	20191227
BR112021012599 A2	20210908	BR20211112599	20191227
CA3124678 AA	20210621	CA20193124678	20191227
CL2021001722 A1	20220218	CL20210001722	20210625
CN113474347 A	20211001	CN201980092839	20191227
CO20210009882 A2	20211029	CO20210009882	20210727
CR20210409 A	20220124	CR20210000409	20191227
EA202191800 A1	20210913	EA20210091800	20191227
EP3902804 A1	20211103	EP20190845797	20191227
HK40061677 A1	20220602	HK20226051155	20220404
HK40062088 A1	20220610	HK20226050160	20220317
ID2022PID00144 A	20220103	ID2021P0005760	20191227
IL284324 AA	20210831	IL20190284324	20191227
IN202117031892 A	20211210	IN202117031892	20210715
JO20210171 A1	20230130	JO20210000171	20191227
JP2022516882 T2	20220303	JP20210538125T	20191227
KR20220050832 A	20220425	KR20217023830	20191227
MA54609 A	20220406	MA20190054609	20191227
MX2021007833 A1	20211026	MX20210007833	20191227
PE20212303 A1	20211210	PE20210001090	20191227
RU2021121996 A	20230127	RU20210121996	20191227
SG11202106627W A1	20210729	SG20211106627	20191227
TW202039489 A	20201101	TW20190148080	20191227
US2022098203 AA	20220331	US20210418406	20191227
VN84025 A	20220225	VN20210004577	20191227
WO20139992 A1	20200702	WO2019US68653	20191227

Priority Numbers: US20180785574P [20181227]; WO2019US68653 [20191227]; US20190418406 [20191227]

Probable Patent Assignee: LES LABORATOIRES SERVIER SAS

Assignees: AGIOS PHARMACEUTICALS INC; LES LABORATOIRES SERVIER SAS; SERVIER LAB; LES LABORATOIRES SERVIER INDUSTRIE

Non Std Assignees: KONTEATIS ZENON D; LI MINGZONG; REZNIK SAMUEL K; SUI ZHIHUA; TRAVINS JEREMY M; LES LABORATOIRES SERVIER; 50 RUE CARNOT 92284 SURESNES CEDEX



Inventors: TRAVINS JEREMY M; SUI ZHIHUA; REZNIK SAMUEL K; LI MINGZONG; KONTEATIS ZENON D; ZENON D KONTEATIS; MINGZONG LI; SAMUEL K REZNIK; ZHIHUA SUI; JEREMY M TRAVINS; KONTEATIS ZENON; REZNIK SAMUEL; TRAVINS JEREMY; LI MING ZONG

Non Std Inventors: KONTEATIS ZENON D Z; LI MINGZONG M; REZNIK SAMUEL K S; TRAVINS JEREMY M J

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR LLP; SMART AND BIGGAR LP; ESTUDIO CAREY LTDA; CARPMAELS AND RANSFORD LLP; DEACONS; LIU SHEN AND ASSOCIATES; MAROLITA SETIATI; REINHOLD COHN AND PARTNERS; VICTORIA LILIANA MEJIA TREJO; CONG TY TNHH TAM NHIN VA LIEN DANH; VISION AND ASSOCIATES CO LTD; LUCCI JOSEPH ET AL; BAKER AND HOSTETLER LLP


Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

34. Family 75673694 (US2021030765 AA)

[View in PatBase](#)

Title
[EN] HEMATOPOIESIS-ENHANCING AGENT

Abstract
[EN] The purpose of the invention is to provide a novel hematopoiesis-promoting agent and a medicament comprising the hematopoiesis-promoting agent as an active ingredient for preventing or treating anemia, in particular refractory anemia. The present invention provides a hematopoiesis-promoting agent comprising an S-adenosylmethionine synthase inhibitor.



International Class: A61K31/196; A61K31/5517; A61K31/56; A61K45/00; A61P7/06; C12N5/078; C12N9/99; C12Q1/00; C12Q1/02; C12Q1/48; C12Q1/66; A61K31/22; C12N5/0789; A61K31/19; A61K31/198; A61P43/00; C12N9/10

Cooperative Patent Class: A61K31/19; A61K31/196; A61K31/198; A61K31/22; A61K31/5517; A61K45/00; A61P43/00; A61P7/06; C12N2501/125; C12N2501/14; C12N2501/2303; C12N2501/26; C12N2501/39; C12N2501/999; C12N2506/11; C12N5/0641; C12N5/0647; C12N9/10; C12N9/99; C12Q1/25; C12Q1/48; G01N2333/91171; G01N2500/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
JP2019163994 A1	20210311	JP20200501088T	20190225
US11554124 BB	20230117	US20200975439	20190225
US2021030765 AA	20210204	US20200975439	20190225
WO19163994 A1	20190829	WO2019JP07121	20190225

Priority Numbers: JP20180032469 [20180226]; WO2019JP07121 [20190225]

Probable Patent Assignee: TOHOKU UNIV

Assignees: TOHOKU UNIV; UNIV TOHOKU

Inventors: IGARASHI KAZUHIKO; KATO HIROKI; ISHII YUSHO; NGUYEN CHI LONG; HARIGAE HIDEO

Agent(s): WENDEROTH LIND AND PONACK LLP; WENDEROTH LIND AND PONACK LLP; IP FIRM SHUWA


Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

35. Family 89923998 (WO22036033 A2)

[View in PatBase](#)

Title
[EN] SOLID STATE FORMS OF AN ORGANIC COMPOUND

Abstract
[EN] Provided herein are various solid state forms, including salts as well as various crystalline and amorphous forms, of Compound I which is represented by the structural formula: Also provided are pharmaceutical compositions comprising these materials, methods for their manufacture, uses thereof for treating conditions, including but not limited to conditions that would benefit from inhibition of methionine adenosyltransferase 2a (MAT2A).



International Class: A61K31/519; A61P35/00; C07D487/04; A61K47/38; A61K9/10; A61K9/16

Cooperative Patent Class: A61K9/1617; A61K9/1635; A61K9/1652; A61K9/2013; A61K9/2054; A61P35/00; C07D487/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR123228 AA	20221109	AR2021P102263	20210812
TW202227446 A	20220716	TW20210129859	20210812
WO22036033 A2	20220217	WO2021US45656	20210812
WO22036033 A3	20220421	WO2021US45656	20210812
WO22036033 A4	20220623	WO2021US45656	20210812

Priority Numbers: US20200064866P [20200812]

Probable Patent Assignee: SERVIER PHARMACEUTICALS LLC

Assignees: SERVIER PHARMACEUTICALS LLC; RIOS LIZARRAGA JOSE LUIS

Inventors: DEPEW KRISTOPHER; GRENIER LOUIS; LANE BENJAMIN S; SIMONE ERIC; SIZEMORE JACOB PAUL; RIOS LIZARRAGA JOSE LUIS; RIOS LIZARRAGA JOSE; LANE BENJAMIN; SIZEMORE JACOB

Agent(s): PALOVICH TRACY U ET AL; BAKER AND HOSTETLER LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

36. Family 89924030 (WO22036067 A1)

[View in PatBase](#)

Title
[EN] COMBINATION THERAPIES FOR USE IN TREATING CANCER

Abstract
[EN] The compound of Formula (I), or pharmaceutically acceptable salts thereof, is useful in, among other things, the treatment of cancer and provides a therapeutic advantage when used in combination with other agents as herein described compared to treatment with each agent when administered alone.

International Class: A61K31/502; A61K31/519; A61P35/00; C07D487/04; A61K31/337; A61K31/352; A61K31/416; A61K31/4184; A61K31/4402; A61K31/4439; A61K31/444; A61K31/473; A61K31/5025; A61K31/517; A61K31/55; A61K31/551; A61K31/5517

Cooperative Patent Class: A61K31/337; A61K31/436; A61K31/4535; A61K31/496; A61K31/502; A61K31/519; A61K31/5377; A61K31/555; A61K31/635; A61K31/706; A61K31/7068; A61K33/243; A61K45/06; A61P35/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR123227 AA	20221109	AR2021P102262	20210812
TW202227082 A	20220716	TW20210129858	20210812
WO22036067 A1	20220217	WO2021US45702	20210812
WO22036067 A4	20220407	WO2021US45702	20210812

Priority Numbers: US20200064786P [20200812]


Probable Patent Assignee: SERVIER PHARMACEUTICALS LLC

Assignees: SERVIER PHARMACEUTICALS LLC

Inventors: HYER MARC LEE; KALEV PETAR; MARJON KATYA; MARKS KEVIN; LI FU; LEE HYER MARC; HYER MARC

Agent(s): LUCCI JOSEPH ET AL; BAKER AND HOSTETLER LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW




37. Family 83762081 (US2022340976 AA)

[View in PatBase](#)

Title
[EN] RAPID PREDICTION OF DRUG RESPONSIVENESS

Abstract
[EN] The present disclosure relates to compositions and methods for rapid prediction, based upon early single cell transcriptomic assessment of a biopsied sample obtained from a subject, of whether a subject will be responsive to a drug.



International Class: C12Q1/6886; G06N20/00; G06N3/08; G01N33/15; G01N33/50; G01N33/94

Cooperative Patent Class: C12Q1/6886; C12Q2600/106; C12Q2600/156; C12Q2600/158; G01N2500/10; G01N33/5008; G06N20/00; G06N3/08

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2022340976 AA	20221027	US20220639532	20200901
WO21046027 A1	20210311	WO2020US48896	20200901

Priority Numbers: US20190894924P [20190902]; WO2020US48896 [20200901]; US20200639532 [20200901]

Probable Patent Assignee: BROAD INST INC

Assignees: BROAD INST INC; DANA FARBER CANCER INST INC

Inventors: AGUIRRE ANDREW J; VAZQUEZ FRANCISCA; TSHERNIAK AVIAD; MCFARLAND JAMES; PAOLELLA BRENTON

Agent(s): COWLES CHRISTOPHER R ET AL; BURNS AND LEVINSON LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

38. Family 79218094 (US2022162705 AA)

[View in PatBase](#)

Title
[EN] METHOD FOR PREDICTING THE RESPONSE TO CANCER IMMUNOTHERAPY IN CANCER PATIENTS


Abstract
[EN] The present invention relates to methods, kits, systems and uses thereof for prediction of the response or resistance to and/or benefit from a cancer immunotherapy of a subject suffering from or being at risk of developing a neoplastic disease, in particular breast cancer, based on the measurement(s) of expression level(s) of at least one marker in samples of said subject. Equally, the present invention relates to methods, kits, systems and uses thereof for predicting the outcome from the cancer immunotherapy treatment in said subject based on the measurement(s) of the expression level(s) of the at least one marker in samples of said subject. Further, the present invention relates to the cancer immunotherapy for use in the treatment of the neoplastic disease, in particular breast cancer, in the subject and to methods for cancer immunotherapy treatment by using the cancer immunotherapy according to the methods of the present invention.

International Class: C12Q1/6886
Cooperative Patent Class: C12Q1/6886; C12Q2600/106; C12Q2600/158
Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3887548 A1	20211006	EP20190808852	20191129
US2022162705 AA	20220526	US20210297944	20191129
WO20109570 A1	20200604	WO2019EP83124	20191129

Priority Numbers: EP20180209672 [20181130]; WO2019EP83124 [20191129]
Probable Patent Assignee: CHARITE UNIVERSITAETSMEDIZIN BERLIN
Assignees: UNIV BERLIN CHARITE; GBG FORSCHUNGS GMBH
Non Std Assignees: CHARITE UNIVERSITAETSMEDIZIN BERLIN
Inventors: DENKERT CARSTEN; SINN BRUNO; LOIBL SIBYLLE; WEBER KARSTEN; KARN THOMAS
Agent(s): VOSSIUS AND PARTNER PATENTANWAELTE RECHTSANWAELTE MBB; VOSSIUS AND PARTNER NO 31

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



39. Family 91057470 (WO22082048 A1)

[View in PatBase](#)

Title
[EN] METHODS OF TREATING BREAST CANCER

Abstract
[EN] The present disclosure provides methods and compositions useful for treating metastatic breast cancer in a subject in need thereof. The methods include measuring gene expression in breast cancer cells obtained from the subject, and administering an anticancer therapeutic to the subject.

International Class: C12Q1/6886; G01N33/571
Cooperative Patent Class: A61P35/00; C12Q1/6886; C12Q2600/156; C12Q2600/158

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO22082048 A1	20220421	WO2021US55285	20211015

Priority Numbers: US20200092255P [20201015]

Probable Patent Assignee: HOPE CITY


Assignees: HOPE CITY

Non Std Assignees: CITY OF HOPE

Inventors: NATH ARITRO; BILD ANDREA

Agent(s): CHEN YUWEI ET AL; MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



40. Family 51636202 (US2012196874 AA)

[View in PatBase](#)

Title
[EN] STILBENE ANALOGS AND METHODS OF TREATING CANCER

Abstract
[EN] Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring.

International Class: A61K31/136; A61P35/00; C07C15/52; C07C211/45; A61K31/4164; A61K31/495; C07C211/48; C07C211/56; C07C211/60; C07D233/64; C07D295/073; G01N33/68; C07C211/52; C07C291/04; C07D495/04; G01N33/574; G01N33/58; A61K31/085; A61K31/4174; A61K49/00; A61P43/00; C07C211/54; C07C43/215; C07D295/06; C12Q1/02; G01N33/53; A61K31/05; A61K31/09; A61K31/4188; C07C39/21; C07C43/23; C12Q1/68; G01N33/566; A61K31/03; A61K31/44

Cooperative Patent Class: A61K31/03; A61K31/44; A61P35/00; A61P43/00; C07C211/48; C07C211/52; C07C211/56; C07C211/60; C07C291/04; C07C39/21; C07C43/23; C07D233/64; C07D295/073; C07D495/04; C09B23/148; G01N2800/52; G01N33/57484; G01N33/582

US Class: 1/1; 435/6.11; 435/6.110S; 436/501; 436/501S; 436/86; 436/86S; 514/255.03; 514/255.030P; 514/387; 514/387S; 514/396; 514/396S; 514/645; 514/645S; 514/646; 514/646S; 514/720; 514/720S; 514/733; 514/733S; 514/741; 544/395; 544/395S; 548/304.1; 548/304.100S; 548/346.1; 548/346.100S; 564/300; 564/300S; 564/305; 564/442; 564/442S; 568/646; 568/646S; 568/729; 568/729S

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2826034 AA	20130726	CA20122826034	20120127
CN103764604 A	20140430	CN201280013655	20120127
CN103764604 B	20170208	CN201280013655	20120127
CN105622431 A	20160601	CN201610121358	20120127
CN110015962 A	20190716	CN201811183180	20120127
CN110015962 B	20220315	CN201811183180	20120127
DE602012025728 D1	20170105	DE201260025728T	20120127
EP2673250 A2	20131218	EP20120739698	20120127
EP2673250 A4	20140625	EP20120739698	20120127
EP2673250 B1	20161123	EP20120739698	20120127
JP2014512337 T2	20140522	JP20130551378T	20120127
MX2013008750 A1	20140425	MX20130008750	20120127
MX344772 B	20170106	MX20130008750	20120127
US2012196874 AA	20120802	US20120360109	20120127
US2014249161 AA	20140904	US20140192616	20140227
US8664276 BB	20140304	US20120360109	20120127
US9132102 BB	20150915	US20140192616	20140227
WO12103457 A2	20120802	WO2012US22938	20120127
WO12103457 A3	20121011	WO2012US22938	20120127

Priority Numbers: US20110437341P [20110128]; US20110439118P [20110203]; WO2012US22938 [20120127]; CN201280013655 [20120127]; EP20120739698 [20120127]; US20120360109 [20120127]; US20140192616 [20140227]


Probable Patent Assignee: OF KENTUCKY RESEARCH FOUNDATION UNIV

Assignees: UNIV KENTUCKY; ZHANG WEN; WATT DAVID S; LIU CHUNMING; SVIRIPA VITALIY; SVIRIPA VITALIY M; UNIV OF KENTUCKY; UNIV KENTUCKY RES FOUND; WATT DAVID

Non Std Assignees: OF KENTUCKY UNIV; SVIRIPA VITALTY; SVIRIPA VITALTY M; OF KENTUCKY RESEARCH FOUNDATION UNIV; OF KENTUCKY RESEARCH FOUNDATION LEXINGTON UNIV; UNIVERSITY OF KENTUCKY

Inventors: ZHANG WEN; WATT DAVID S; SVIRIPA VITALIY; LIU CHUNMING; SVIRIPA VITALIY M; DAVID S WATT; CHUNMING LIU; VITALIY M SVIRIPA; WEN ZHANG; WATT DAVID

Non Std Inventors: SVIRIPA VITALTY; SVIRIPA VITALTY M



Agent(s): ROBIC; EISENFUEHR SPEISER PATENTANWAELTE RECHTSANWAELTE PARTGMBB; EIP; FRANCISCO JAVIER UHTHOFF ORIVE; MCDERMOTT WILL AND EMERY LLP; TOFFENETTI JUDITH L

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PE; PG; PH; QA; RU; RW; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZM; ZW; ZA

41. Family 89705352 (CN113999232 A)

[View in PatBase](#)

Title
[EN] MAT2A INHIBITORS

Abstract
[EN] The invention discloses an MAT2A inhibitor, and particularly relates to a compound shown in a formula I or pharmaceutically acceptable salt thereof. The definition of each substituent group is described in the specification. The invention also provides a preparation method of the compound.

International Class: A61K31/4162; A61K31/423; A61K31/454; A61K31/5025; A61K31/519; A61K31/53; A61K31/538; A61K31/5386; A61P35/00; C07D413/04; C07D487/04; C07D487/16; C07D519/00

Cooperative Patent Class: A61P35/00; C07D413/04; C07D487/04; C07D487/16; C07D519/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN113999232 A	20220201	CN202010736919	20200728

Priority Numbers: CN202010736919 [20200728]

Probable Patent Assignee: NANJING CHIA TAI TIANQING PHARMACEUTICAL CO LTD

Assignees: NANJING CHIA TAI TIANQING PHARMACEUTICAL CO LTD; CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

Non Std Assignees: NANJING CHIA TAI TIANQING PHARMACEUTICAL CO

Inventors: HUANG DANDAN; SU JINCAI; MA LI; DAI QINGYU; WU YEBIN; ZHANG HUAN; ZUO RUI; WU JIAN; MA CHANGYOU; MIAO LEI; XU DAN; ZHU CHUNXIA; TIAN ZHOUSHAN

42. Family 67441567 (US2019241633 AA)


[View in PatBase](#)

Title
[EN] RNA ENCODING A THERAPEUTIC PROTEIN

Abstract
[EN] The present invention relates to an RNA encoding a therapeutic protein. In particular, the present invention relates to RNA suitable for use as a medicament. The present invention concerns such novel RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament. The present invention also provides the use of the RNA, compositions or kits as disclosed herein for increasing the expression of said encoded protein, in particular in gene therapy.

International Class: A61K31/7088; A61K48/00; C12N15/67; C12N15/85; A61K38/00; C07K14/505; A61K31/7105; A61K45/06; C12N15/113

Cooperative Patent Class: A61K31/7088; A61K31/7105; A61K38/00; A61K45/06; A61K48/00; A61K48/005; C07K14/505; C12N15/113; C12N2310/531



Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3452101 A2	20190313	EP20170727793	20170504
US11078247 BB	20210803	US20180098844	20170504
US2019241633 AA	20190808	US20180098844	20170504
US2022025369 AA	20220127	US20210359902	20210628
WO17191274 A2	20171109	WO2017EP60692	20170504
WO17191274 A3	20180208	WO2017EP60692	20170504

Priority Numbers: WO2016EP60111 [20160504]; WO2017EP60692 [20170504]; US20180098844 [20181102]; US20210359902 [20210628]

Probable Patent Assignee: CUREVAC SE

Assignees: CUREVAC AG

Non Std Assignees: CUREVAC SE

Inventors: FOTIN MLECZEK MARIOLA; HOERR INGMAR

Agent(s): GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH; PARKER HIGHLANDER PLLC; PARKER HIGHLANDER PLLC; VON STOSCH ANDREAS ET AL

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

43. Family 66642805 (JP2017131218 A2)

[View in PatBase](#)

Title

[EN] MEASUREMENT METHOD FOR ASSISTING WITH INSPECTION OF DISEASE FROM EB VIRUS-RELATED NK-CELL LYMPHOPROLIFERATIVE DISEASE TO NK-CELL NEOPLASM PROGRESSION

Abstract

[EN] PROBLEM TO BE SOLVED: To provide a measurement method for assisting with the inspection of disease from EB virus-related NK-cell lymphoproliferative disease to NK-cell neoplasm progression.SOLUTION: A measurement method for assisting with the inspection of disease includes measuring an expression level of at least one gene selected from specific genes: (A-1) GPR82, MYO18B, CYP1B1, S100A8, HBA1, HBA2 and the like, (A-2) RFC2, PLK1, DHFR, CDC45L, PTPN11, BIRC5 and the like, (B-1) TSPO, SHC4, CRTAM, CADM1 and the like, (B-2) TNFRSF10A, CCND2, PDGFRA, FADS1 and the like, (C) ZNF569, ZNF836, PALLD, SOX4, ZNF91, LEF1 and the like, (D-1) MSN, HLA-DPB1, SLC16A3, MYO6 and the like, (D-2) ATAD3A, LOC100129935, TJP1, SSX1 and the like.SELECTED DRAWING: Figure 9

International Class: C12Q1/68; G01N33/569; C12Q1/6813

Family Information

Patent Number	Publication Date	Application Number	Application Date
JP2017131218 A2	20170803	JP20170011642	20170125
JP2021176320 A2	20211111	JP20210122891	20170125


Priority Numbers: JP20160012847 [20160126]; JP20170011642 [20170125]; JP20210122891 [20210728]

Probable Patent Assignee: OKAYAMA UNIV

Assignees: OKAYAMA UNIV; UNIV OKAYAMA

Inventors: OKA TAKASHI; WASHIO KANA; YOSHINO TADASHI

Agent(s): SHOJI TAKASHI; SUKENOBU YURIKO



44. Family 60956874 (US2017270239 AA)

[View in PatBase](#)


Title
[EN] IN VITRO TOXICOGENOMICS FOR TOXICITY PREDICTION

Abstract
[EN] A novel method to predict toxicity and dose-dependent effects of an agent based on transcriptomic data analysis, by determining a predictive toxicogenomics space (PTGS) score. The PTGS score helps to predict and model the toxicity of compounds typically consisting of chemicals, pharmaceuticals, cosmetics and agrochemicals. The invention further comprises methods of deriving the PTGS score, as well as computer programs to calculate PTGS scores.

International Class: C12Q1/68; G16B20/00; G16B25/00; G16B5/00; G16C20/30; G16C20/70; G16B20/20; G16B25/10; G16B5/20; G06F19/00; C12Q1/6876; G16C20/10

Cooperative Patent Class: C12Q1/6876; C12Q2600/142; C12Q2600/158; G16B20/00; G16B20/20; G16B25/00; G16B25/10; G16B5/00; G16B5/20; G16C20/10; G16C20/30; G16C20/70

US Class: 1/1; 435/6.11



Family Information

Patent Number	Publication Date	Application Number	Application Date
DE602015073723 D1	20211014	DE201560073723T	20150528
DK3149204 T3	20211025	DK20150798811T	20150528
EP3149204 A1	20170405	EP20150798811	20150528
EP3149204 A4	20180613	EP20150798811	20150528
EP3149204 B1	20210929	EP20150798811	20150528
US10665323 BB	20200526	US20150313493	20150528
US2017270239 AA	20170921	US20150313493	20150528
WO15183173 A1	20151203	WO2015SE50617	20150528

Priority Numbers: US20140003641P [20140528]; EP20150798811 [20150528]; WO2015SE50617 [20150528]; US20150313493 [20150528]

Probable Patent Assignee: PREDICTOMICS AB

Assignees: PREDICTOMICS AB; PARKKINEN JUUSO; GRAFSTROEM ROLAND; KASKI SAMUEL; KOHONEN PEKKA; GRAFSTROM ROLAND

Non Std Assignees: PREDICTOMICS CERCON AB

Inventors: GRAFSTROEM ROLAND; KOHONEN PEKKA; PARKKINEN JUUSO; KASKI SAMUEL; GRAFSTROM ROLAND

Agent(s): PATENTANWALTE ISENBRUCK BOESL HOERSCHLER PARTG MBB; POTTER CLARKSON LLP; POTTER CLARKSON; HAMILTON BROOK SMITH AND REYNOLDS PC; HAMILTON BROOK SMITH AND REYNOLDS PC; AROS PATENT AB

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

45. Family 72980758 (US2020158716 AA)

[View in PatBase](#)

Title
[EN] CELL ATLAS OF HEALTHY AND DISEASED BARRIER TISSUES

Abstract
[EN] Embodiments disclosed herein provide a cell atlas of barrier tissues from healthy and diseased subject. The atlas was obtained by single cell sequencing of approximately 18,036 cells in a surgical data set and 18,704 cells from scrapings. The present invention discloses novel markers for cell types. Moreover, genes associated with disease, including type 2 inflammation are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for controlling differentiation, proliferation, maintenance and/or function of the cell types disclosed herein. In addition, novel cell types and methods of quantitating, detecting and isolating the cell types are disclosed.

International Class: G16C10/00; C12Q1/6886; G01N33/50; C12Q1/68; G01N33/574; G06F19/00
Cooperative Patent Class: C07K16/28; C12N5/0634; C12Q1/6883; C12Q1/6886; C12Q2600/106; C12Q2600/158; G01N33/5032

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP3655961 A1	20200527	EP20180835203	20180717
EP3655961 A4	20210901	EP20180835203	20180717
US2020158716 AA	20200521	US20180631898	20180717
WO19018441 A1	20190124	WO2018US42557	20180717

Priority Numbers: US20170533639P [20170717]; US20170585534P [20171113]; WO2018US42557 [20180717]; US20180690304P [20180626]; US20180631898 [20180717]

Probable Patent Assignee: MASSACHUSETTS INST TECHNOLOGY


Assignees: MASSACHUSETTS INST TECHNOLOGY; MASSACHUSETTS INST OF TECH

Non Std Assignees: MASSACHUSETTS INST OF TECHNOLOGY

Inventors: SHALEK ALEXANDER K; ORDOVAS MONTANES JOSE

Agent(s): ICELY DOMINIC MICHAEL; IP ASSET PARTNERS; SCHER MICHAEL B ET AL; JOHNSON MARCOU AND ISAACS LLC

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



46. Family 41976109 (US2010137149 AA)

[View in PatBase](#)

Title
[EN] DATA PROCESSING, ANALYSIS METHOD OF GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES

Abstract
[EN] Disclosed are a data processing and analysis method of gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in the amplification of the identified endogenous reference genes. Introduced with the concepts of 'Zero's proportion' and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Out of the 2,087 genes, 13 genes are found to show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTB, and therefore are suitable for the normalization of universal genes having relatively low expression levels.

International Class: C12Q1/06; C12Q1/68; G06F19/00; G16Z99/00; C12Q1/6813; C12Q1/6851; G16B25/00; G16B25/10; C12N15/09; C12M1/00; C40B30/04; G01N33/53; G01N37/00; C40B30/02; C40B40/04; C40B40/08; G06F19/20


Cooperative Patent Class: C12Q1/6813; C12Q1/6851; C12Q2600/166; C40B40/06; G16B25/00; G16B25/10; C12Q2545/101; C12Q2545/113

US Class: 1/1; 435/6; 435/6.11; 435/6.110S; 435/6.12; 435/6.14; 435/6.140S; 435/6S; 435/7.23; 435/7.230S; 506/16; 506/17; 506/17S; 506/8; 506/8P; 702/19; 702/19S

Family Information

Patent Number	Publication Date	Application Number	Application Date	
DE602007053084 D1	20171228	DE200760053084T	20071227	
DE602007060374 D1	20200709	DE200760060374T	20071227	
EP2115158 A1	20091111	EP20070860690	20071227	
EP2115158 A4	20091230	EP20070860690	20071227	
EP2455878 A2	20120523	EP20110166073	20071227	
EP2455878 A3	20140618	EP20110166073	20071227	
EP2455878 B1	20171115	EP20110166073	20071227	
EP3346403 A1	20180711	EP20170194976	20071227	
EP3346403 B1	20200617	EP20170194976	20071227	
ES2814027 T3	20210325	ES20170194976T	20071227	
JP2010514441 T2	20100506	JP20090543947T	20071227	
JP2012228249 A2	20121122	JP20120140384	20120622	
JP2016127827 A2	20160714	JP20150248677	20151221	
JP5934036 B2	20160615	JP20120140384	20120622	
JP6181144 B2	20170816	JP20150248677	20151221	
KR101007926 B1	20110112	KR20070138880	20071227	
KR20080063156 A	20080703	KR20070138880	20071227	
US10304561 BB	20190528	US20170582330	20170428	
US11107552 BB	20210831	US20180129206	20180912	
US2010137149 AA	20100603	US20070521498	20071227	
US2014038833 AA	20140206	US20120631279	20120928	
US2018068057 AA	20180308	US20170582330	20170428	
US2019012429 AA	20190110	US20180129206	20180912	
US9639660 BB	20170502	US20120631279	20120928	
WO08078969 A1	20080703	WO2007KR06890	20071227	

Priority Numbers: KR20060134883 [20061227]; EP20110166073 [20071227]; EP20170194976 [20071227]; WO2007KR06890 [20071227]; EP20070860690 [20071227]; EP20110166073 [20110513]; JP20090543947 [20071227]; JP20090543947T



[20071227]; JP20120140384 [20071227]; JP20150248677 [20151221]; US20120631279 [20120928]; US20170582330 [20170428]; US20090521498 [20090626]; US20180129206 [20180912]

Probable Patent Assignee: GXD BIO CORP

Assignees: GENCURIX INC; ABION INC; SNU R and DB FOUNDATION; REFERENCE BIOLABS CO LTD; SNU R AND DB FOUND; SEOUL NAT UNIV IND FOUNDATION; REFERENCEBIOLABS CO LTD; REFERNCEBIOLABS CO LTD; IN YONG HO; SHIN YOUNG KEE; OH EN SEL; KWON MI JEONG; KOH SANG SEOK

Non Std Assignees: REFERENCE BIOLABS CO; SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION; SEOUL NATIONAL UNIV IND FOUNDATION; GXD BIO CORP; REFERENCEBIOLABS CO; REFERNCEBIOLABS CO

Inventors: SHIN YOUNG KEE; KWON MI JEONG; OH EN SEL; IN YONG HO; KOH SANG SEOK; KWON MI J; IN YONG H; KOH SANG S

Agent(s): OFFICE FREYLINGER SA; KIHN PIERRE EMILE JOSEPH; OFFICE FREYLINGER; GUSTAVO ADOLFO GONZALEZ PECES; KAWAMOTO KAZUYA; OSAKABE SUGURU; SHIMIZU HATSUSHI; HARNESS DICKEY AND PIERCE PLC; HARNESS DICKEY AND PIERCE PLC; EDWARDS ANGELL PALMER AND DODGE LLP; GABRIEL J; LOCKE LORD LLP; LEE WON HEE

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; AL; BA; HR; MK; RS; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

47. Family 86481061 (WO21158792 A1)

[View in PatBase](#)

Title


[EN] METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS

Abstract

[EN] The disclosure is directed to methods of treating autoimmune and inflammatory diseases or disorders using inhibitors of the MAT2A enzyme.

International Class: A61K31/4178; A61P35/00; C07D233/88

Cooperative Patent Class: A61K31/136; A61K31/198; A61K31/22; A61K31/4745; A61K31/519; A61K31/53; A61K31/5377; A61K31/538; A61K31/675; A61K45/06; A61P35/00



Family Information

Patent Number	Publication Date	Application Number	Application Date
WO21158792 A1	20210812	WO2021US16618	20210204

Priority Numbers: US20200970101P [20200204]

Probable Patent Assignee: AGIOS PHARMACEUTICALS INC

Assignees: ROYAL INSTITUTION FOR ADVANCEMENT OF LEARNING MCGILL UNIV; AGIOS PHARMACEUTICALS INC

Inventors: HAYES SEBASTIAN; CHUBUKOV VICTOR; KINGSBURY GILLIAN; RODDY THOMAS; JONES RUSSELL

Non Std Inventors: RODDY THOMAS P; JONES RUSSELL GRAHAM

Agent(s): DOYLE TIMOTHY J ET AL; BAKER AND HOSTETLER LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

48. Family 84877870 (US2021140982 AA)

[View in PatBase](#)

Title


[EN] IDENTIFICATION OF SPATIAL BIOMARKERS OF BRAIN DISORDERS AND METHODS OF USING THE SAME

Abstract

[EN] Provided herein are methods of detecting biomarkers and/or candidate biomarkers for brain disorders and uses of the same.

International Class: A61K45/06; G01N33/53; G01N33/68; A61K31/337; A61K31/704; G01N33/574; C12Q1/6886

Cooperative Patent Class: A61K45/06; C12Q1/6883; C12Q2600/158; G01N2458/10; G01N2800/2821; G01N2800/52; G01N33/5308; G01N33/6896; A61K31/133; A61K31/138; A61K31/337; A61K31/4196; A61K31/4535; A61K31/5685; A61K31/57; A61K31/704; C12Q1/6886; G01N2496/00; G01N33/57415; G01N33/57484; A61P35/00; C12Q2600/106; G01N33/57407



Family Information

Patent Number	Publication Date	Application Number	Application Date
US2021140982 AA	20210513	US20200073242	20201016
US2021199660 AA	20210701	US20200100106	20201120
US2021222253 AA	20210722	US20210153681	20210120

Priority Numbers: US20190923330P [20191018]; US20190939517P [20191122]; US20200964063P [20200121]; US20200073242 [20201016]; US20200980116P [20200221]; US20200035324P [20200605]; US20200979681P [20200221]; US20200100106 [20201120]; US20200108273P [20201030]; US20200114404P [20201116]; US20210153681 [20210120]

Probable Patent Assignee: 10X GENOMICS INC

Assignees: 10X GENOMICS INC

Inventors: UYTINGCO CEDRIC; WILLIAMS STEPHEN R; BENT ZACHARY; CHEW JENNIFER

49. Family 65978391 (US2018371551 AA)

[View in PatBase](#)

Title
[EN] MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER

Abstract
[EN] The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a MAT2A inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a MAT2A inhibitor, comprising assessing whether the tumor cell is absent an MTAP gene whereby cells that are MTAP null are sensitive to inhibition by MAT2A inhibitors.

International Class: A61K31/015; A61K31/505; A61K45/00; A61P35/00; A61K; A61P; A61K31/136; A61K31/166; A61K31/4164; A61K31/495; A61P43/00; C12N15/09; C12N15/113; C12N9/99; C12Q1/6809; C12Q1/6876; G01N33/50; A61K31/167; C12Q1/02; A61K31/03; C12Q1/68; G01N33/15; G01N33/53; A61K31/44; C12Q1/6886

Cooperative Patent Class: A61K31/015; A61K31/03; A61K31/136; A61K31/44; A61K31/505; A61P35/00; C12Q1/6886; C12Q2600/156

US Class: 1/1; 514/275

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2016364855 AA	20180705	AU20160364855	20161202
AU2016364855 BB	20190829	AU20160364855	20161202
CA3006743 AA	20180529	CA20163006743	20161202
CN108601752 A	20180928	CN201680080863	20161202
EA201891304 A1	20190131	EA20180091304	20161202
EP3383375 A1	20181010	EP20160819232	20161202
HK1261140 A1	20191227	HK20190121012	20190315
IL259773 A0	20180731	IL20160259773	20161202
JP2018537473 T2	20181220	JP20180528729T	20161202
JP2021098736 A2	20210701	JP20210037941	20161202
JP6877429 B2	20210526	JP20180528729T	20161202
KR20180100125 A	20180907	KR20187018814	20161202
MX2018006781 A1	20181109	MX20180006781	20161202
SG11201804360X A1	20180628	SG20181104360	20161202
US2018371551 AA	20181227	US20160780494	20161202
WO17096165 A1	20170608	WO2016US64619	20161202

Priority Numbers: US20150262750P [20151203]; US20160297572P [20160219]; WO2016US64619 [20161202]; JP20180528729T [20161202]; JP20180528729 [20161202]; JP20210037941 [20210310]; US20160780494 [20161202]

Probable Patent Assignee: SERVIER PHARMACEUTICALS LLC


Assignees: AGIOS PHARMACEUTICALS INC; LES LABORATOIRES SERVIER; SERVIER LAB; KATYA MARJON; SUNG EUN CHOE

Non Std Assignees: MARJON KATYA; CHOE SUNG EUN; SERVIER PHARMACEUTICALS LLC

Inventors: MARJON KATYA; CHOE SUNG EUN; KATYA MARJON; SUNG EUN CHOE

Agent(s): SPRUSON AND FERGUSON; BERESKIN AND PARR LLP SENCRL SRL; PLOUGMANN VINGTOFT A S; LECOME INTELLECTUAL PROPERTY AGENT LTD; KAWAMOTO KAZUYA; OSAKABE SUGURU; SHIMIZU HATSUSHI; SERGIO LUIS OLIVARES LOBATO; PERDOK MONIQUE M REG NO 42

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



50. Family 75149604 (CN110029158 A)

[View in PatBase](#)

Title
[EN] MARFAN SYNDROME DETECTION PANEL AND ITS APPLICATION

Abstract
[EN] The invention provides a Marfan syndrome detection panel and its application, which relate to the field of medical and health care, The panel provided by the invention can detect a plurality of 124 genes related to the Marfan syndrome at one time, significantly improves the positive detection rate of the mutation sites of the Marfan syndrome, can be used for the early diagnosis of the Marfan syndrome, and timely treat the diseases, and reduces the prevalence and mortality, which solves the technical problem that the genetic detection coverage in the prior art is not comprehensive and the missed diagnosis rate is high, and the panel detection provided by the invention has low cost and wide universality.

International Class: C12N15/11; C12Q1/6883
Cooperative Patent Class: C12Q1/6883; C12Q2600/156

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN110029158 A	20190719	CN201910101980	20190201
CN110029158 B	20210330	CN201910101980	20190201

Priority Numbers: CN201910101980 [20190201]
Probable Patent Assignee: UNIV PEKING THIRD HOSPITAL
Assignees: UNIV PEKING THIRD HOSPITAL
Non Std Assignees: PEKING UNIV THIRD HOSPITAL
Inventors: ZHI XU; QIAO JIE; ZHU XIAOHUI; ZHANG ZHE; LI XUEMIN; YAN LIYING; QIN MENG

51. Family 57877846 (US2016109453 AA)

[View in PatBase](#)

Title
[EN] LUNG CANCER DIAGNOSTIC METHOD AND MEANS

Abstract
[EN] The present invention discloses a method of diagnosing lung cancer by using specific markers from a set, having diagnostic power for lung cancer diagnosis and distinguishing lung cancer types in diverse samples.

International Class: G01N33/574; G01N33/50
Cooperative Patent Class: G01N2800/60; G01N33/57423
US Class: 435/6.12; 435/7.92; 436/501; 506/9

Family Information

Patent Number	Publication Date	Application Number	Application Date
DE602014039990 D1	20190214	DE201460039990T	20140523
DE602014075284 D1	20210318	DE201460075284T	20140523
EP2806274 A1	20141126	EP20130169067	20130524
EP3004887 A2	20160413	EP20140727779	20140523
EP3004887 B1	20190116	EP20140727779	20140523
EP3418746 A2	20181226	EP20180185502	20140523
EP3418746 A3	20190116	EP20180185502	20140523
EP3418746 B1	20210224	EP20180185502	20140523
US10156570 BB	20181218	US20140893712	20140523
US2016109453 AA	20160421	US20140893712	20140523
WO14187959 A2	20141127	WO2014EP60667	20140523
WO14187959 A3	20150205	WO2014EP60667	20140523

Priority Numbers: EP20130169067 [20130524]; EP20140727779 [20140523]; WO2014EP60667 [20140523]; EP20180185502 [20140523]

Probable Patent Assignee: AIT AUSTRIAN INST OF TECHNOLOGY GMBH
Assignees: AIT AUSTRIAN INST TECHNOLOGY; AIT AUSTRIAN INST OF TECH GMBH; AIT AUSTRIAN INST TECH GMBH
Non Std Assignees: AIT AUSTRIAN INST OF TECHNOLOGY GMBH
Inventors: WEINHAEUSEL ANDREAS; WEINHAUSEL ANDREAS

Agent(s): DEHMEL AND BETTENHAUSEN PATENTANWAELTE PARTMBB; SONN AND PARTNER PATENTANWAELTE; NORTON ROSE FULBRIGHT US LLP; NORTON ROSE FULBRIGHT US LLP

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

52. Family 83355511 (WO21023609 A1)

[View in PatBase](#)

Title
[EN] COMBINATION OF A TYPE I PROTEIN ARGININE METHYLTRANSFERASE (TYPE I PRMT) INHIBITOR AND A METHIONINE ADENOSYLTRANSFERASE II ALPHA (MAT2A) INHIBITOR

Abstract
[EN] The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a methionine adenosyltransferase II alpha (MAT2A) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a MAT2A inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor.


International Class: A61K31/415; A61K31/4155; A61K31/519; A61K45/06; A61P35/00
Cooperative Patent Class: A61K31/415; A61K31/4155; A61K31/519; A61K45/06; A61P35/00

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO21023609 A1	20210211	WO2020EP71460	20200730

Priority Numbers: US20190882164P [20190802]
Probable Patent Assignee: GLAXOSMITHKLINE PLC
Assignees: GLAXOSMITHKLINE IP DEV LTD
Non Std Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD; GLAXOSMITHKLINE PLC
Inventors: KRUGER RYAN G; LARAIO JENNY; MOHAMMAD HELAI
Agent(s): SHORE ANDREW DAVID

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



53. Family 43649260 (US2011003008 AA)

[View in PatBase](#)

Title
[EN] MESENCHYMAL STEM CELL PARTICLES

Abstract
[EN] We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.

International Class: A61K35/12; A61K35/28; C12N5/07; C12N5/0775; C12N5/06; A61K9/16; A61P11/02; A61P13/12; A61P17/00; A61P17/02; A61P17/06; A61P19/08; A61P25/16; A61P25/28; A61P29/00; A61P3/10; A61P35/00; A61P37/02; A61P9/00; A61P9/04; A61P9/10; C12N5/0735; A61K38/00; A61P17/12; A61P37/04; A61P37/08; C07K14/47; C12P21/00; C12N5/00; A61K35/00; A61K47/24; A61K47/28; A61K9/00; A61K9/10; C12N1/00

Cooperative Patent Class: A61K35/12; A61K35/28; A61K47/24; A61K47/28; A61K9/0019; A61K9/10; A61L2300/30; A61P11/02; A61P13/12; A61P17/00; A61P17/02; A61P17/06; A61P17/12; A61P19/08; A61P25/16; A61P25/28; A61P29/00; A61P3/10; A61P35/00; A61P37/02; A61P37/04; A61P37/08; A61P9/00; A61P9/04; A61P9/10; C12N5/00; C12N5/0663; C12N5/0667

US Class: 1/1; 424/450; 424/489; 424/520; 424/520P; 435/317.1; 435/317.100S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2009215934 AA	20090827	AU20090215934	20090221
AU2009215934 BB	20131024	AU20090215934	20090221
AU2009215934 CA	20140508	AU20090215934	20090221
AU2014200380 AA	20140206	AU20140200380	20140122
CN102014934 A	20110413	CN200980114014	20090221
CN102014934 B	20140820	CN200980114014	20090221
CN104127438 A	20141105	CN201410352490	20090221
CN104127438 B	20210108	CN201410352490	20090221
CY1116467 T1	20170315	CY20151100588T	20150707
DE602009030479 D1	20150521	DE200960030479T	20090221
DK2254586 T3	20150615	DK20090712571T	20090221
EP2254586 A1	20101201	EP20090712571	20090221
EP2254586 B1	20150408	EP20090712571	20090221
ES2537516 T3	20150609	ES20090712571T	20090221
HR20150510 T1	20150605	HR20150000510	20150513
HU026536 T2	20160628	HU20090712571T	20090221
JP2011513217 T2	20110428	JP20100547594T	20090221
JP5718648 B2	20150513	JP20100547594T	20090221
KR101640381 B1	20160718	KR20107019584	20090221
KR20100122087 A	20101119	KR20107019584	20090221
PL2254586 T3	20150930	PL20090712571T	20090221
PT2254586 T	20150518	PT20090712571T	20090221
SI2254586 T1	20150731	SI20090031203T	20090221
TR201505175 T4	20150521	TR20150005175T	20090221
US10780128 BB	20200922	US20140444105	20140728
US2011003008 AA	20110106	US20090918122	20090221
US2015190430 AA	20150709	US20140444105	20140728
US2017189449 AA	20170706	US20170404774	20170112
WO09105044 A1	20090827	WO2009SG00062	20090221



Priority Numbers: US20080066671P [20080222]; WO2009SG00062 [20090221]; AU20090215934 [20090221]; AU20140200380 [20140122]; CN200980114014 [20090221]; US20080066671 [20080222]; EP20090712571 [20090221]; US20140444105 [20140728]; US20100918122 [20100818]; US20090918122 [20090221]; US20170404774 [20170112]

Probable Patent Assignee: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH A STAR

Assignees: AGENCY SCIENCE TECH AND RES; AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH ASTARSTAR; AGENCY FOR SCIENCE TECH AND RES A STAR; AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR; LIM SAI KIANG

Non Std Assignees: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH A STAR; AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH; AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (A STAR)

Inventors: LIM SAI KIANG; KIANG LIM SAI

Non Std Inventors: SAI KIANG LIM

Agent(s): ALLENS ARTHUR ROBINSON PATENT AND TRADE MARKS ATTORNEYS; ALLENS PATENT AND TRADE MARK ATTORNEYS; BOEHMERT AND BOEHMERT ANWALTSPARTNERSCHAFT MBB PATENTANWAELTE RECHTSANWAELTE; KEHOE LAURA ELLEN; CURELL MIREIA; HANDE MUMCUOGLU; FITZGERALD MARK J; NIXON PEABODY LLP; NIXON PEABODY LLP; DAVID S RESNICK; NIXON PEABODY LLP; KHOO CHONG YEE; CANTAB LLP

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AL; BA; RS; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

54. Family 80554875 (WO20167952 A1)

[View in PatBase](#)

Title
[EN] MAT2A INHIBITORS

Abstract
[EN] Disclosed herein are compounds of Formula (I), that inhibit Methionine Adenosyltransferase 2A (MAT2A) activity. In particular, the invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the invention.

International Class: A61K31/4178; A61P35/00; C07D233/88; C07D401/12; C07D403/12; C07D413/04; C07D417/04

Cooperative Patent Class: A61P35/00; C07D233/88; C07D401/12; C07D403/12; C07D413/04; C07D417/04

Family Information

Patent Number	Publication Date	Application Number	Application Date
WO20167952 A1	20200820	WO2020US17934	20200212

Priority Numbers: US20190804352P [20190212]

Probable Patent Assignee: MIRATI THERAPEUTICS INC


Assignees: MIRATI THERAPEUTICS INC

Inventors: BOBINSKI THOMAS; MARX MATTHEW

Non Std Inventors: BOBINSKI THOMAS P; MARX MATTHEW ARNOLD

Agent(s): SARUSSI STEVEN J; MCDONNELL BOEHNEN HULBERT AND BERGHOFF LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



55. Family 64526581 (US2017157197 AA)


[View in PatBase](#)

Title

[EN] METHODS OF USING GM604 IN MODULATING ALS DISEASE BIOMARKERS LEADING TO PROGNOSIS AND THERAPEUTIC TREATMENT FOR ALS DISEASE

Abstract

[EN] Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement. In a recent Phase 2A double-blind, randomized, placebo controlled clinical trial with GM604 (AKA MNTF, GM6), where ALS patients were treated with six doses of GM604 for two weeks and then continued to be evaluated for disease progression until 10 weeks after cessation of GM604 treatment, it was demonstrated that GM604 can modulate expression of ALS disease related genes, through pathways that bring about homeostasis of pertinent ALS biomarkers. The statistical significance in biomarker changes also correlate with treatment effects in clinical observations. This correlation of disease progression with the modulation of the biomarkers suggest that GM604 can be used effectively in modulating ALS disease biomarkers, and consequently can be used for prognosis of ALS disease progression and therapeutic treatment to slow down ALS disease progression. The biomarker modulation can be a measure of drug efficacy.



International Class: A61K38/08; C12Q1/68; C12Q1/6883; G01N33/68; A61P25/28; C07K7/06; G01N33/50

Cooperative Patent Class: A61K38/08; A61P25/28; C12Q1/6883; G01N2800/28; G01N2800/52; G01N33/6896

US Class: 1/1; 514/17.7

Family Information

Patent Number	Publication Date	Application Number	Application Date
US10632169 BB	20200428	US20160374950	20161209
US2017157197 AA	20170608	US20160374950	20161209
WO16210123 A1	20161229	WO2016US39007	20160623

Priority Numbers: US20150185278P [20150626]; WO2016US39007 [20160623]; US20160374950 [20161209]

Probable Patent Assignee: GENERVON BIOPHARMACEUTICALS LLC

Assignees: GENERVON BIOPHARMACEUTICALS LLC

Inventors: KO PUI YUK DOROTHY; SWINDELL WILLIAM R; SWINDELL WILLIAM; KINDY MARK S; BOJANOWSKI KRZYSZTOF

Agent(s): CANADY AND LORTZ LLP; CANADY AND LORTZ LLP; CANADY KAREN S; COLLETT JAMES; GENERVON BIOPHARMACEUTICALS LLC

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

56. Family 74498384 (CN109811048 A)

[View in PatBase](#)

Title

[EN] PROBE SET APPLIED TO DETECTING PATHOPOIESIA/SUSCEPTIBILITY GENES OF HEREDITARY AORTIC DISEASES

Abstract

[EN] The invention provides application of a reagent for detecting pathopoiesia/susceptibility genes of hereditary aortic diseases in preparing a product for diagnosing the aortic diseases. The reagent can capture varieties of pathopoiesia and/or susceptibility genes of the aortic diseases and can detect 34 related genes at most. The reagent and the product containing the reagent disclosed by the invention can explain pathogenesis of aortic disease patients, can evaluate aortic disease risk and dangerous factors, can provide reference for molecular genetic diagnosis for affected individuals, general survey of high-risk groups, screening of the pathogenetic high-risk groups in family members, corresponding genetic counselling and prenatal diagnosis interference and can reduce the incidence rate of the aortic diseases. Meanwhile, a probe set, a chip and a kit disclosed by the invention have the advantages of high efficiency, multiple detection loci, accuracy, convenience in operation, good specificity, high flexibility, quickness, strong practicability and low cost.

International Class: A61K45/00; A61K49/00; A61P9/00; C12N15/11; C12Q1/6883

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN109811048 A	20190528	CN201910088712	20190130

Priority Numbers: CN201910088712 [20190130]

Probable Patent Assignee: CHINESE PLA GENERAL HOSPITAL

Assignees: CHINESE PLA GENERAL HOSPITAL; MYGENOSTICS INC; GENERAL HOSPITAL OF PLA

Inventors: HE KUNLUN; WU JIAN; JIA QIAN; SHI JINLONG; ZHAO XIAOJING; JIA ZHILONG; LIU JIXUAN; ZHANG MANLI; MA JUNFENG; MENG FANFEI

57. Family 74109788 (CN109680001 A)

[View in PatBase](#)

Title

[EN] PREPARATION METHOD OF MAT2A GENE INTERFERENCE VECTOR FOR REDUCING LIPID DEPOSITION OF INTRAMUSCULAR FAT CELLS

Abstract

[EN] The invention relates to a preparation method of an MAT2A gene interference vector for reducing lipid deposition of intramuscular fat cells, aiming at effectively solving the problem of the interference of MAT2A on the lipid deposition of the intramuscular fat cells so as to prepare a medicine for treating liver cancer. The method comprises the following steps of: constructing a lentivirus MAT2A interference vector; transfecting the lentivirus MAT2A interference vector into a 293T cell culture medium containing a lentivirus vector; packaging recombinant lentivirus pLentiH1-MAT2AshRNA; carryingout titering on the recombinant lentivirus pLentiH1-MAT2AshRNA and calculating the virus titer; detecting pLentiH1-MAT2AshRNA infected pig intramuscular fat cells and detecting differentiation lipiddeposition of the pig intramuscular fat cells through a interference vector MAT2A-shRNA2 (Short-Hairpin RNA2), thus reducing the aggregation capability of lipid droplets in an sh-MAT2A treatment groupby 48 to 52 percent. The method provided by the invention is easy and sensitive to operate, is stable and reliable and can be used for remarkably reducing the expression level of MAT2A mRNA and protein in fat cells; the lipid content level in the fat cells is also remarkably reduced, and the interference effect on the lipid deposition of the pig intramuscular fat cells is realized.

International Class: A61K31/7088; A61P1/16; A61P35/00; C12N15/867

Cooperative Patent Class: A61K31/7088; A61P1/16; A61P35/00; C12N15/86; C12N2740/15043; C12N2740/15052; C12N2800/107

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN109680001 A	20190426	CN201811646760	20181230

Priority Numbers: CN201811646760 [20181230]

Probable Patent Assignee: XINYANG COLLEGE AGRICULTURE AND FORESTRY

Assignees: XINYANG COLLEGE AGRICULTURE AND FORESTRY; XINYANG AGRICULTURE AND FORESTRY UNIV

Non Std Assignees: XINYANG COLLEGE OF AGRICULTURE AND FORESTRY


Inventors: ZHAO CUNZHEN; GUO XIAOQIU; WANG JUNFENG; CHEN BIN; LIU JIA

58. Family 60764010 (CN105039342 A)

[View in PatBase](#)

Title
[EN] SIRNA CAPABLE OF INHIBITING MAT2A GENETIC EXPRESSION AND APPLICATION OF SIRNA

Abstract
[EN] The invention discloses siRNA capable of inhibiting MAT2A genetic expression and application of the siRNA. The positive-sense strand of siRNA MAT2A-1 capable of inhibiting the MAT2A genetic expression is shown as SEQ ID NO:2, and the antisense strand of the siRNA MAT2A-1 is shown as SEQ ID NO:3. The positive-sense strand of siRNA MAT2A-2 capable of inhibiting the MAT2A genetic expression is shown as SEQ ID NO:4, and the antisense strand of the siRNA MAT2A-2 is shown as SEQ ID NO:5. Lentivirus vector transfection liver cancer cells of lentivirus expression vector combination overexpression MAT1A genes built according to the siRNA inhibiting the MAT2A genetic expression successfully inhibit hepatocellular carcinoma angiogenesis, migration, invasion and lung metastasis, the nucleotide sequence of the MAT1A genes is shown as the 256th-144th bases of SEQ ID NO.1. The siRNA can be further applied to preparing medicine treating liver cancer diseases and has high theoretical and application value.



International Class: A61K31/713; A61P35/00; A61P35/04; C12N15/113; C12N15/867

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN105039342 A	20151111	CN201510476981	20150806
CN105039342 B	20171201	CN201510476981	20150806

Priority Numbers: CN201510476981 [20150806]

Probable Patent Assignee: FAN WENZHE

Assignees: LI JIAPING; FAN WENZHE; YAO XUEHUA; WANG RUIZHI

Non Std Assignees: LIJIA PING

Inventors: LI JIAPING

59. Family 60049917 (US2015225719 AA)

[View in PatBase](#)

Title
[EN] PHARMACEUTICAL COMPOSITION FOR TREATING LIVER DISEASES

Abstract
[EN] The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.

International Class: A61K31/7105; A61P1/16; A61P35/00; A61K31/4375; C12N15/113; A61K48/00; C07H21/02; C07H21/04

Cooperative Patent Class: A61K31/4375; A61K31/7105; A61P1/16; A61P35/00; C12N15/113; C12N15/1137; C12N2310/141; C12N2320/30; C12N2320/32

US Class: 1/1; 424/450; 514/280; 514/44A; 536/23.1

Family Information

Patent Number	Publication Date	Application Number	Application Date
TW201531295 A	20150816	TW20140104537	20140212
TWI533873 B	20160521	TW20140104537	20140212
US2015225719 AA	20150813	US20140496280	20140925
US2016076039 AA	20160317	US20150873275	20151002
US9469854 BB	20161018	US20150873275	20151002


Priority Numbers: TW20140104537 [20140212]; US20140496280 [20140925]; US20150873275 [20151002]

Probable Patent Assignee: ACADEMIA SINICA

Assignees: ACADEMIA SINICA; ACAD SINICA

Inventors: LO TING FANG; CHEN SHUI TEIN; TSAI WEI CHUNG

Agent(s): BACON AND THOMAS PLLC




60. Family 57439047 (US2014287939 AA)

[View in PatBase](#)

Title
[EN] BIOMARKER(S) FOR EARLY DETECTION / DIAGNOSIS/ PROGNOSIS OF GASTRIC CANCER

Abstract
[EN] The present invention discloses the nine biomarkers including HIF1A, FAM84B, CRIP2, GSN, RPL15, DLG1, MAT2A, PGBD2 and ID3 are respectively selected according to their specific and unique expression profile in the gastric cancer cells or gastric cancer tissue. Therefore, the nine biomarkers are related to diagnose gastric cancer, such as detecting early gastric cancer, staging gastric cancer, predicting prognosis of gastric cancer and diagnosing lymph node metastasis. By analyzing the expression value of at least one biomarker of a sample from a subject, the subject can be precisely diagnose the risk about gastric cancer.

International Class: C07H21/04; C12Q1/68; G01N33/68
Cooperative Patent Class: C12Q1/6886; C12Q2600/158; G01N2800/56; G01N33/57446; G01N2800/50
US Class: 435/6.12; 435/7.1; 435/7.92; 436/501; 506/18; 506/9; 530/350



Family Information

Patent Number	Publication Date	Application Number	Application Date
TW201437223 A	20141001	TW20130109695	20130319
TWI507412 B	20151111	TW20130109695	20130319
US2014287939 AA	20140925	US20130034750	20130924
US2016060708 AA	20160303	US20150871626	20150930

Priority Numbers: TW20130109695 [20130319]; US20130034750 [20130924]; US20150871626 [20150930]
Probable Patent Assignee: TAICHUNG VETERANS GENERAL HOSPITAL
Assignees: TAICHUNG VETERANS GENERAL HOSPITAL
Inventors: WU JUN YING; WU CHUN YING

61. Family 43780716 (US2009281061 AA)

[View in PatBase](#)

Title

[EN] IMPAIRED ALLELES OF GENES INVOLVED IN METABOLIC PATHWAYS AND METHODS FOR DETECTING AND USING THE SAME

Abstract

[EN] The invention is directed to enzyme variants, responsiveness thereof to cofactors, and in vivo assays for testing the activity of enzyme variants as well as the responsiveness thereof to cofactors.

International Class: C12N15/52; C12Q1/25; C12Q1/68; C12N; C12Q; A61K31/4415; A61K31/519; A61K45/00; A61P25/18; A61P25/24; A61P25/28; A61P27/02; A61P27/06; A61P3/00; A61P35/00; A61P7/02; A61P9/00; A61P9/10; C12M1/00; C12N15/09; G01N33/15; G01N33/50; G01N33/53; G01N33/573; A61K31/675; A61P25/00; C07H21/00; C07H21/04; C40B40/04; C40B40/08

Cooperative Patent Class: A61P25/00; A61P25/18; A61P25/24; A61P25/28; A61P27/02; A61P27/06; A61P3/00; A61P35/00; A61P7/02; A61P9/00; A61P9/10; C12N15/52; C12Q1/25; C12Q1/6883; C12Q1/6895; C12Q2600/106; C12Q2600/142; C12Q2600/156; G01N2333/39; G01N2800/04; G01N33/82

US Class: 435/5; 435/5S; 435/6; 435/6.12; 435/6.120S; 435/6.17; 435/6.170S; 435/6S; 506/17; 506/17S; 514/89; 514/89P; 536/23.1; 536/23.100S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2009228015 AA	20091001	AU20090228015	20090327
BRPI0910097 A2	20151215	BR2009PI10097	20090327
CA2719733 AA	20100924	CA20092719733	20090327
CN102027134 A	20110420	CN200980117301	20090327
EP2276857 A1	20110126	EP20090724590	20090327
EP2276857 A4	20120125	EP20090724590	20090327
HK1149594 A1	20111007	HK20110103665	20110412
IL208456 A0	20101230	IL20090208456	20090327
IN07554DN2010 A	20110909	IN2010DN07554	20101027
JP2011519267 T2	20110707	JP20110502127T	20090327
KR20100134067 A	20101222	KR20107023846	20090327
MX2010010476 A1	20101125	MX20100010476	20090327
RU2010143882 A	20120510	RU20100143882	20090327
SG189711 A1	20130531	SG20130002287	20090327
US2009281061 AA	20091112	US20090413506	20090327
WO09121044 A1	20091001	WO2009US38703	20090327
WO09121044 A8	20101104	WO2009US38703	20090327
ZA201006987 A	20120125	ZA20100006987	20090327

Priority Numbers: US20080040020P [20080327]; WO2009US38703 [20090327]; WO2009US38703 [20090410]; US20090413506 [20090327]

Probable Patent Assignee: OF CALIFORNIA UNIV


Assignees: UNIV CALIFORNIA; UNIV CALIFORINA; MARINI NICHOLAS; RINE JASPER

Non Std Assignees: THE UNIV OF CALIFORNIA; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE REGENTS OF THE UNIVERSITY OF CALIFORINA; THE UNIV OF CALIFORINA; UNIV OF CALIFORNIA; OF CALIFORNIA UNIV

Inventors: RINE JASPER; MARINI NICHOLAS; NICHOLAS MARINI; JASPER RINE

Agent(s): SPRUSON AND FERGUSON; BORDEN LADNER GERVAIS LLP; WALTON SEAN MALCOLM; MEWBURN ELLIS LLP; WU XINYU; AOKI ATSUSHI; FUKUMOTO TSUMORU; ISHIDA TAKASHI; KOGA TETSUJI; MIGUEL ALEJANDRO ESTEVA WURTS; SPRUSON AND FERGUSON ASIA PTE LTD; KING SPALDING LLP; LORENZ TODD A ET AL; KING AND SPALDING LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN;



CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

62. Family 32400174 (US2005255450 AA)

[View in PatBase](#)

Title

[EN] METHODS OF IDENTIFYING LEAD COMPOUNDS THAT MODULATE TOXICITY OF NEUROTOXIC POLYPEPTIDES

Abstract

[EN] Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided.

International Class:

C12N1/18; C12Q1/00; C12Q1/02; C12Q1/68; G01N33/68; A61K48/00; C12N1/19; C12N15/81; A01N63/00; C12N1/00; C12Q1/04; A01N63/04; C07H21/04; C12N15/11; G01N33/53; G01N33/569

Cooperative Patent Class:

C12N15/81; C12Q1/02; C12Q1/025; G01N2500/04; G01N33/6896

US Class:

424/9.2; 424/9.200P; 424/93.5; 424/93.51; 435/254.2; 435/254.200S; 435/254.21; 435/254.210S; 435/255.1; 435/255.2; 435/29; 435/29S; 435/32; 435/375; 435/4; 435/4P; 435/6; 435/6.1; 435/6.13; 435/6.16; 435/6.160S; 435/7.31; 514/44.00A; 514/44A; 536/23.1; 536/23.5; 536/24.3

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2005255450 AA	20051117	US20040003216	20041203
US2009068111 AA	20090312	US20080272031	20081117
US2013084596 AA	20130404	US20120418848	20120313
US7452670 BB	20081118	US20040003216	20041203
US8133679 BB	20120313	US20080272031	20081117
US8735072 BB	20140527	US20120418848	20120313

Priority Numbers:

US20030527215P [20031204]; US20040003216 [20041203]; US20080272031 [20081117]; US20120418848 [20120313]

Probable Patent Assignee:

WHITEHEAD INST FOR BIOMEDICAL RESEARCH

Assignees:

WHITEHEAD BIOMEDICAL INST; UNIV WASHINGTON; LINDQUIST SUSAN L; MUCHOWSKI PAUL J; OUTEIRO TIAGO

Non Std Assignees:

WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH; OF WASHINGTON UNIV; WHITEHEAD INST FOR BIOMEDICAL RESEARCH; NATIONAL INSTITUTES OF HEALTH (NIH) US DEPT OF HEALTH AND HUMAN SERVICES (DHHS) US GOVERNMENT; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALTH AND HUMAN SERVICES DHHS US GOVERNMENT; NATIONAL INST; WHITEHEAD INST; UNIVERSITY OF WASHINGTON; WASHINGTON UNIV; NATIONAL INSTITUTES OF HEALTH; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALT

Inventors:

LINDQUIST SUSAN L; MUCHOWSKI PAUL J; OUTEIRO TIAGO

Non Std Inventors:

MUCHOWSKI PAUL; LINDQUIST SUSAN

Agent(s):

TOWNSEND AND TOWNSEND AND CREW LLP; FISH AND RICHARDSON PC

63. Family 23918049 (US2004013663 AA)

[View in PatBase](#)

Title

[EN] IDENTIFICATION OF SEQUENCES PARTICULARLY USEFUL FOR THE DIAGNOSIS AND IDENTIFICATION OF THERAPEUTIC TARGETS FOR OSTEOARTHRITIS

Abstract

[EN] The invention relates to the identification and selection of sequences which demonstrate particular advantage in identifying individuals having osteoarthritis (OA). The invention also provides a selection of sequences particularly useful in diagnosing the degree of advancement of osteoarthritis of an individual and in the identification of novel therapeutic targets for OA. The invention further provides for the use of these sequences as a tool to diagnose disease progression and to monitor the efficacy of therapeutic regimens.


International Class: C12Q1/68; A61K45/00; A61P19/00; A61P19/02; C12N1/15; C12N1/19; C12N1/21; C12N15/09; C12N5/10; G01N33/15; G01N33/50; G01N33/53; G01N37/00; A61B; C40B30/00; C40B40/08; C07H21/04; C40B30/04; C40B40/06; G16B25/10; C12Q1/02; A61K38/00; C12N15/12; C12P19/34; G01N33/48; G06F19/00; C12M3/00; G01N21/64; A61B1/00; A61K39/00; A61K39/395; C07K14/47; C07K14/74; C12N5/06; C12P21/02; G01N33/569

Cooperative Patent Class: C12Q1/6809; C12Q1/6883; C12Q1/6886; C12Q2600/158; Y10T436/143333; A61K38/00; A61P19/00; A61P19/02; C12N15/11; C12Q2600/112; Y02A90/10; C12Q1/6837; G16B25/00; G16B25/10; C12Q2600/136; G01N21/6486

US Class: 424/130.1; 424/130.100P; 424/185.1; 424/185.100P; 435/287.2; 435/287.200S; 435/320.1; 435/320.100S; 435/325; 435/325S; 435/6; 435/6.1; 435/6.100S; 435/6.11; 435/6.110P; 435/6.12; 435/6.120P; 435/6.120S; 435/6.13; 435/6.130P; 435/6.14; 435/6.140P; 435/6.140S; 435/6.16; 435/6.160P; 435/6.160S; 435/6.18; 435/6.180P; 435/6.180S; 435/69.1; 435/69.100S; 435/6P; 435/6S; 435/7.1; 435/7.100S; 435/7.22; 435/7.220S; 435/7.1; 435/91.1; 435/91.2; 435/91.200S; 436/501; 436/501S; 436/94; 436/94S; 506/9; 530/35; 530/350; 530/350S; 536/23.1; 536/23.5; 536/23.500S; 536/24.3; 536/24.300S; 536/24.31; 536/24.33; 536/25.4; 702/20; 702/20S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU200018536 A1	20000724	AU20000018536	20000105
AU200018536 A5	20000724	AU20000018536D	20000105
AU2002237124 AA	20020919	AU20020237124	20020228
AU2002237124 AB	20020919	AU20020237124	20020228
AU2002237124 AI	20020919	AU20020237124	20020228
AU2002237124 BB	20080306	AU20020237124	20020228
AU2004249318 AA	20041229	AU20040249318	20040621
AU2008200903 AA	20080403	AU20080200903	20080226
BRPI0207657 A	20041026	BR2002PI07657	20020228
CA2359816 AA	20010706	CA20002359816	20000105
CA2359816 C	20100803	CA20002359816	20000105
CA2439504 AA	20030828	CA20022439504	20020228
CA2530191 AA	20051220	CA20042530191	20040621
CA2588072 AA	20070511	CA20052588072	20051115
CA2702148 AA	20000713	CA20002702148	20000105
CA2702148 C	20140304	CA20002702148	20000105
CA2832266 AA	20000713	CA20002832266	20000105
CN101415836 A	20090422	CN200480023549	20040621
EP1404868 A2	20040407	EP20020703416	20020228
EP1643893 A2	20060412	EP20040785715	20040621
EP1643893 A4	20071205	EP20040785715	20040621
EP1815020 A2	20070808	EP20050848795	20051115
EP1815020 A4	20100106	EP20050848795	20051115
HK1090530 A1	20061229	HK20060111240	20061012
HK1090530 A3	20061229	HK20060111240	20061012
IL172652 A0	20060410	IL20040172652	20040621



Patent Number	Publication Date	Application Number	Application Date
JP2004536575 T2	20041209	JP20020570759T	20020228
JP2007528704 T2	20071018	JP20060517766T	20040621
JP2008295459 A2	20081211	JP20080212602	20080821
KR20040055733 A	20040626	KR20037011506	20020228
SG141418 A1	20080428	SG20070191588	20040621
US2004013663 AA	20040122	US20020242535	20020912
US2004014059 AA	20040122	US20020268730	20021009
US2004037841 AA	20040226	US20020085783	20020228
US2004241726 AA	20041202	US20040812707	20040330
US2004241727 AA	20041202	US20040812731	20040330
US2004241728 AA	20041202	US20040812764	20040330
US2004241729 AA	20041202	US20040813097	20040330
US2004248169 AA	20041209	US20040812737	20040330
US2004248170 AA	20041209	US20040812777	20040330
US2004265868 AA	20041230	US20040812702	20040330
US2004265869 AA	20041230	US20040812716	20040330
US2005003394 AA	20050106	US20040812782	20040330
US2005042630 AA	20050224	US20040816357	20040401
US2005079514 AA	20050414	US20040812827	20040330
US2005123938 AA	20050609	US20040809675	20040325
US2005191637 AA	20050901	US20040803737	20040318
US2005196762 AA	20050908	US20040803759	20040318
US2005196763 AA	20050908	US20040803857	20040318
US2005196764 AA	20050908	US20040803858	20040318
US2005208505 AA	20050922	US20040803648	20040318
US2005208519 AA	20050922	US20040989191	20041115
US2006134635 AA	20060622	US20040802875	20040312
US2006134637 AA	20060622	US20040812797	20040330
US2007031841 AA	20070208	US20030601518	20030620
US2007054282 AA	20070308	US20050313302	20051220
US2007105121 AA	20070510	US20040812646	20040330
US2009098564 AA	20090416	US20080287629	20081010
US2010092983 AA	20100415	US20090573863	20091005
US2010092984 AA	20100415	US20090573865	20091005
US2010124745 AA	20100520	US20090573856	20091005
US2010124746 AA	20100520	US20090587382	20091005
US2010203519 AA	20100812	US20090587384	20091006
US2010203520 AA	20100812	US20090587385	20091005
US2011003294 AA	20110106	US20100757918	20100409
US2011003295 AA	20110106	US20100757921	20100409
US2011003296 AA	20110106	US20100757928	20100409
US2011003297 AA	20110106	US20100757930	20100409
US2011003298 AA	20110106	US20100757931	20100409
US2011008779 AA	20110113	US20100757914	20100409
US2011008780 AA	20110113	US20100757925	20100409
US2011014614 AA	20110120	US20100757934	20100409
US2011020808 AA	20110127	US20100777042	20100510
US2011059447 AA	20110310	US20100757923	20100409

Patent Number	Publication Date	Application Number	Application Date
US2011123989 AA	20110526	US20100917428	20101101
US2011275069 AA	20111110	US20100803688	20100701
US2013123128 AA	20130516	US20120665786	20121031
US2013165336 AA	20130627	US20120603094	20120904
US2013190197 AA	20130725	US20120584369	20120813
US2013261008 AA	20131003	US20120681292	20121119
US7432049 BB	20081007	US20020085783	20020228
US7473528 BB	20090106	US20040813097	20040330
US7598031 BB	20091006	US20020268730	20021009
US7662558 BB	20100216	US20040803858	20040318
US7713702 BB	20100511	US20080287629	20081010
US7906278 BB	20110315	US20020242535	20020912
US8067173 BB	20111129	US20100757918	20100409
US8101358 BB	20120124	US20100757914	20100409
US8110358 BB	20120207	US20100757931	20100409
US8114597 BB	20120214	US20100757921	20100409
US8133674 BB	20120313	US20100757928	20100409
US8133675 BB	20120313	US20100757934	20100409
US8148072 BB	20120403	US20100757930	20100409
US8257922 BB	20120904	US20100757925	20100409
US8258284 BB	20120904	US20100777042	20100510
US8669058 BB	20140311	US20120584369	20120813
WO0040749 A2	20000713	WO2000CA00005	20000105
WO0040749 A3	20010719	WO2000CA00005	20000105
WO02070737 A2	20020912	WO2002CA00247	20020228
WO02070737 A3	20040129	WO2002CA00247	20020228
WO02070737 C1	20021031	WO2002CA00247	20020228
WO02070737 C2	20031002	WO2002CA00247	20020228
WO04112589 A2	20041229	WO2004US20836	20040621
WO04112589 A3	20081211	WO2004US20836	20040621
WO06055524 A2	20060526	WO2005US41268	20051115
WO06055524 A3	20081224	WO2005US41268	20051115

Priority Numbers: US1990115125P [19990106]; US20000477148 [20000104]; WO2000CA00005 [20000105]; US20010271955P [20010228]; US20010275017P [20010312]; US20010305340P [20010713]; WO2002CA00247 [20020228]; US20030601518 [20030620]; US20040809675 [20040325]; WO2004US20836 [20040621]; AU20020237124 [20020228]; AU20080200903 [20080226]; US20040989191 [20041115]; WO2005US41268 [20051115]; CA20002359816 [20000105]; CA20132702148 [20131119]; CA20002832266 [20000105]; CA20002702148 [20000105]; US20020242535 [20020912]; US20020085783 [20020228]; US20020268730 [20021009]; US20040812707 [20040330]; US20040802875 [20040312]; US20040812731 [20040330]; US20040812764 [20040330]; US20040813097 [20040330]; US20040812737 [20040330]; US20040812777 [20040330]; US20040812702 [20040330]; US20040812716 [20040330]; US20040812782 [20040330]; US20040816357 [20040401]; US20040812827 [20040330]; US20040803737 [20040318]; US20040803759 [20040318]; US20040803857 [20040318]; US20040803858 [20040318]; US20040803648 [20040318]; US20040812797 [20040330]; US20050313302 [20051220]; US20040812646 [20040330]; US20080287629 [20081010]; WO2004US20836 [20040620]; US20090573863 [20091005]; US20090573865 [20091005]; US20090573856 [20091005]; US20090587382 [20091005]; US20090587384 [20091006]; US20090587385 [20091005]; US20100757918 [20100409]; US20100757921 [20100409]; US20100757928 [20100409]; US20100757930 [20100409]; US20060568730 [20060217]; DE20031038277 [20030820]; US20100757931 [20100409]; US20100757914 [20100409]; US20100757925 [20100409]; US20100757934 [20100409]; US20100777042 [20100510]; US20100757923 [20100409]; US20100917428 [20101101]; US20100803688 [20100701]; US20120665786 [20121031]; US20120603094 [20120904]; US20120584369 [20120813]; US20120681292 [20121119]

Probable Patent Assignee: GENENEWS CORP

Assignees: CHOONG CHIN LIEW; LIEW CHOONG CHIN; CHONDROGENE INC; GENENEWS INC; GENENEWS CORP; MARSHALL WAYNE E; ZHANG HONGWEI; DEMPSEY ADAM; CHAO SAMUEL; GENE NEWS INC; CHONDROGENE; CHONDROGENE LTD; YAGER THOMAS; WILLIAMS KATHLEEN M

Non Std Assignees: GENENEWS LTD; YAGER THOMAS D; MARSHALL WAYNE; CHONDROGENE LIMITED; STAGEZERO LIFE SCIENCES LTD

Inventors: LIEW CHOONG CHIN; CHOONG CHIN LIEW; MARSHALL WAYNE E; ZHANG HONGWEI; DEMPSEY ADAM; YAGER THOMAS; CHAO SAMUEL; MARSHALL WAYNE; LIEW CHOONG CHIIN

Non Std Inventors: WAYNE E MARSHALL; HONGWEI ZHANG; YAGER THOMAS D; WAYNE MARSHALL; CHOONG CHIIN LIEW

Agent(s): WRAYS; BERESKIN AND PARR LLP SENCRL SRL; BERESKIN AND PARR; CHINA PATENT AGENT HK LTD; PALMER AND DODGE LLP KATHLEEN M WILLIAMS; EDWARDS ANGELL PALMER AND DODGE LLP; KATHLEEN; WILLIAMS KATHLEEN; AMY; DECLoux AMY; EDWARDS WILDMAN PALMER LLP; SUNSTEIN KANN MURPHY AND TIMBERS LLP

Designated States: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR; BG; CZ; EE; HU; PL; RO; SI; SK; AL; BA; HR; IS; LT; LV; MK; YU; AE; AM; AU; AZ; BB; BF; BJ; BR; BY; CA; CF; CG; CI; CM; CN; CR; CU; DM; GA; GD; GE; GH; GM; GN; GW; ID; IL; IN; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; MA; MD; MG; ML; MN; MR; MW; MX; NE; NO; NZ; RU; SD; SG; SL; SN; SZ; TD; TG; TJ; TM; TT; TZ; UA; UG; US; UZ; VN; ZA; ZW; AG; BZ; CO; DZ; EC; GQ; MZ; OM; PH; TN; ZM; BW; EG; NA; NI; PG; SC; SY; VC; KM; KN; LY; NG; SM

64. Family 34556985 (US2009048266 AA)

[View in PatBase](#)

Title
[EN] EFFECTS OF INHIBITORS OF FGFR3 ON GENE TRANSCRIPTION

Abstract
[EN] Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.

International Class: C12Q1/68; A61K45/00; A61P35/00; C12N15/09; G01N33/15; G01N33/50; G01N33/53; G01N33/574; G01N37/00; A61K31/33; A61K31/496; A61K31/497; G01N33/566
Cooperative Patent Class: A61P35/00; C12Q1/6886; C12Q2600/106; C12Q2600/136; C12Q2600/158
US Class: 435/6; 435/6.1; 435/6.100S; 435/6.11; 435/6.110S; 435/6.12; 435/6.120S; 435/6.13; 435/6.130S; 435/6.14; 435/6S; 435/7.1; 435/7.9; 435/7.900S; 435/7.92; 435/7.920S; 436/501; 436/501S; 514/253.07; 514/253.070P

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2006321602 AA	20070614	AU20060321602	20061207
AU2006321602 BB	20120308	AU20060321602	20061207
BRPI0619548 A2	20111004	BR2006PI19548	20061207
CA2630597 AA	20080521	CA20062630597	20061207
CN101326292 A	20081217	CN200680046301	20061207
EP1960547 A2	20080827	EP20060840156	20061207
EP2546359 A1	20130116	EP20120163693	20061207
IN05205DN2008 A	20080926	IN2008DN05205	20080617
JP2009523410 T2	20090625	JP20080544659T	20061207
KR20080080525 A	20080904	KR20087013675	20061207
MX303652 B	20120924	MX20080007364	20061207
RU2008127252 A	20100120	RU20080127252	20061207
US2009048266 AA	20090219	US20060096222	20061207
US2012149714 AA	20120614	US20120400833	20120221
US8158360 BB	20120417	US20060096222	20061207
WO07067968 A2	20070614	WO2006US61766	20061207
WO07067968 A3	20070823	WO2006US61766	20061207

Priority Numbers: US20050748944P [20051208]; WO2006US61766 [20061207]; EP20060840156 [20061207]; US20050748944 [20051208]; US20060096222 [20061207]; US20120400833 [20120221]; US20080096222 [20080619]

Probable Patent Assignee: NOVARTIS AG

Assignees: NOVARTIS AG; STEWART KEITH; ROWE MICHAEL; MASIH KHAN ESTHER; TRUDEL SUZANNE; HEISE CARLA; MOLER EDWARD; NOVARTS AG; NOVARTIS INT AG

Inventors: STEWART KEITH; ROWE MICHAEL; MASIH KHAN ESTHER; TRUDEL SUZANNE; HEISE CARLA; MOLER EDWARD; MICHAEL ROWE; CARLA HEISE; EDWARD MOLER; KEITH STEWART; SUZANNE TRUDEL; HEISE CARLA C

Non Std Inventors: ESTHER MASIH KHAN; CARLA C HEISE

Agent(s): DAVIES COLLISON CAVE; DAVIES COLLISON CAVE PTY LTD; FETHERSTONHAUGH AND CO; ROTH PETER RICHARD ET AL; NOVARTIS PHARMA AG; UEXKÜLL & STOLBERG; CESAR RAMOS DE MIGUEL; NOVARTIS CORPORATE INTELLECTUAL PROPERTY; NOVARTIS;CORPORATE INTELLECTUAL PROPERTY; COZETTE M

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AU; AZ; BA; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; HR; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; MK; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RS; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

65. Family 42141526 (US2010273671 AA)

[View in PatBase](#)

Title

[EN] METHOD FOR THE DETERMINATION AND THE CLASSIFICATION OF RHEUMATIC CONDITIONS

Abstract

[EN] Methods for the determination and the classification of a rheumatic condition in a synovial sample of a subject afflicted with a rheumatic condition are disclosed. Methods include the steps of determining in the level of expression of at least 20 genes or gene fragments in the synovial sample and identifying whether the level of expression of the genes in the sample correlates with the presence of a rheumatic condition. Kits are also described for the determination and the classification of rheumatic conditions which contain a low density microarray having probes suitable for hybridizing with at least 20 genes or gene fragments. On the basis of the hybridization results, the rheumatic condition is determined.

International Class: C12Q1/68; C40B30/04; C40B40/06

Cooperative Patent Class: C12Q1/6883; C12Q2600/158

US Class: 506/16; 506/16S; 506/9; 506/9P

Family Information

Patent Number	Publication Date	Application Number	Application Date
DE602008018364 D1	20121025	DE200860018364T	20080229
EP2132343 A1	20091216	EP20080717304	20080229
EP2132343 B1	20120829	EP20080717304	20080229
US2010273671 AA	20101028	US20080528615	20080229
WO08104608 A1	20080904	WO2008EP52532	20080229

Priority Numbers: EP20070447014 [20070301]; EP20080717304 [20080229]; WO2008EP52532 [20080229]

Probable Patent Assignee: CATHOLIQUE DE LOUVAIN UNIV


Assignees: CLINIQUES UNIVERSITAIRES SAINT LUC; CLINIQUES UNIVERSITAIRES SAINT; UNIV LOUVAIN; UNIV CATHOLIQUE LOUVAIN; HOUSSIAU FREDERIC; GUTIERREZ ROELENS ILSE; LAUWERYS BERNARD; VAN DEN EYNDE BENOIT

Non Std Assignees: CATHOLIQUE DE LOUVAIN UNIV; UNIVERSITE CATHOLIQUE DE LOUVAIN

Inventors: GUTIERREZ ROELENS ILSE; VAN DEN EYNDE BENOIT; HOUSSIAU FREDERIC; LAUWERYS BERNARD

Agent(s): BUNGARTZ CHRISTOPHERSEN PARTNERSCHAFT MBB PATENTANWALTE; BRANTS JOHAN P E; DE CLERCQ BRANTS AND PARTNERS; VANHALST KOEN; DE CLERCQ AND PARTNERS; KNOBBE MARTENS OLSON AND BEAR LLP; BRANTS JOHAN PHILIPPE EMILE

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AE; AG; AL; AM; AO; AU; AZ; BA; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; ME; MG; MK; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PG; PH; RS; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



66. Family 42258049 (US2010166727 AA)

[View in PatBase](#)

Title
[EN] S-ADENOSYLMETHIONINE AND METHYLTHIOADENSOSINE IN CHEMOPREVENTION AND TREATMENT OF COLON POLYPS AND CANCER

Abstract
[EN] The present invention relates to S-adenosylmethionine (SAmE), methylthioadenosine (MTA) for the treatment of disease. More specifically, the invention relates to SAmE and MTA methods and compositions for the chemoprevention and treatment of colon polyps and cancer.

International Class: A61K31/7042; A61K31/7076; A61K38/43; A61P1/00; A61P1/06; A61P35/00; A61K31/70

Cooperative Patent Class: A61K31/70; A61K45/06; A61P1/06; A61P35/00

US Class: 424/94.5; 424/94.500P; 514/46; 514/46S

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2010166727 AA	20100701	US20080594567	20080402
WO08122054 A1	20081009	WO2008US59188	20080402

Priority Numbers: US20070909646P [20070402]; US20080594567 [20080402]; WO2008US59188 [20080402]

Probable Patent Assignee: OF SOUTHERN CALIFORNIA UNIV


Assignees: UNIV SOUTHERN CALIFORNIA; LU SHELLY C

Non Std Assignees: NATIONAL INSTITUTES OF HEALTH; NATIONAL INSTITUTES OF HEALTH (NIH) US DEPT OF HEALTH AND HUMAN SERVICES (DHHS) US GOVERNMENT; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALTH AND HUMAN SERVICES DHHS US GOVERNMENT; OF SOUTHERN CALIFORNIA UNIV; SOUTHERN CALIFORNIA UNIV; NATIONAL INSTITUTES OF HEALTH NIH US DEPT OF HEALT; UNIVERSITY OF SOUTHERN CALIFORNIA

Inventors: LU SHELLY C

Agent(s): HOGAN AND HARTSON LLP; MCCLURE LAWRENCE J ET AL; HOGAN AND HARTSON LLP

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



67. Family 44005318 (US2009286689 AA)

[View in PatBase](#)

Title
[EN] METHODS FOR ANALYZING DIFFERENTIAL GENE EXPRESSION ASSOCIATED WITH MYELOPROLIFERATIVE DISORDERS (MPD) CANCER DISEASE

Abstract
[EN] The present application relates to gene analysis and, in particular, to gene expression profiling for identifying molecular signature of cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer and studying cancer. More particularly, the application is directed to a method for analyzing differential gene expression associated with cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer comprising detection of upregulation and/or downregulation of a pool of polynucleotide sequences in a cell or tissue sample, said pool corresponding to all or part the polynucleotide sequences, subsequences or complements thereof, of the genes listed in Tables 1, 2 and 3.

International Class: C12Q1/68; C40B30/00; C40B40/06
Cooperative Patent Class: C12Q1/6886; C12Q2600/106; C12Q2600/158; C12Q2600/178
US Class: 435/6; 435/6.11; 435/6.110S; 435/6S; 506/16; 506/16S; 506/7; 506/7P

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2009286689 AA	20091119	US20070953899	20071211

Priority Numbers: US20060874357P [20061212]; US20070953899 [20071211]
Probable Patent Assignee: INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Assignees: INST NAT SANTE RECH MED
Non Std Assignees: INSERM INST NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSERM; INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA REC
Inventors: BIRNBAUM DANIEL; CERVERA NATHALIE; LELIEVRE HELENE
Agent(s): HARNESS DICKEY AND PIERCE PLC



68. Family 40766290 (US2009275633 AA)

[View in PatBase](#)

Title
[EN] NOVEL TUMOUR SUPPRESSOR

Abstract
[EN] A method of diagnosing cancer includes the steps of, in a sample obtained from a subject, determining the level or activity of HDAC2. A reduced level or activity of HDAC2 is indicative of cancer. HDAC2 protein expression is preferably determined. Indirect determination of HDAC2 expression is also possible, preferably by looking at the expression of genes selected from NCOA4, CTSB, TBCD, PPP2R4 and CORO1C. Methods for predicting the probability of successful treatment of cancer using a hydroxamic acid based HDAC inhibitor and for selecting suitable cancer treatment regimens can also be based upon determining the level or activity of HDAC2. Methods of treatment of cancer may be based upon use of carboxylic acid based HDAC inhibitors or by reconstituting HDAC2 activity.

International Class: A61K31/19; A61K48/00; G01N33/574; C12Q1/34; C12Q1/68

Cooperative Patent Class: A61K31/19; G01N2500/04; G01N2800/52; G01N33/57419

US Class: 435/18; 435/18S; 435/6; 435/6.14; 435/6.140S; 514/44.00AP; 514/44A

Family Information

Patent Number	Publication Date	Application Number	Application Date
CA2639070 AA	20080917	CA20072639070	20070413
EP2010916 A2	20090107	EP20070732390	20070413
US2009275633 AA	20091105	US20070225807	20070413
WO07122369 A2	20071101	WO2007GB01347	20070413
WO07122369 A3	20080327	WO2007GB01347	20070413
WO07122369 C1	20081113	WO2007GB01347	20070413

Priority Numbers: EP20060112667 [20060413]; US20060744800P [20060413]; WO2007GB01347 [20070413]; EP20070732390 [20070413]; US20070225807 [20070413]

Probable Patent Assignee: ONCOMETHYLOME SCIENCES SA

Assignees: ESTELLER MANUEL; ONCOMETHYLIME SCIENCES S A; ONCOMETHYLOME SCIENCES SA; BALDOCK SHARON CLAIRE; ESTELLER MANEL

Non Std Assignees: ONCOMETHYLIME SCIENCES SA

Inventors: ESTELLER MANUEL; ESTELLER MANEL

Agent(s): GOWLING LAFLEUR HENDERSON LLP; SPENCER MATTHEW PETER; FOLEY AND LARDNER LLP SUITE 500; FOLEY AND LARDNER LLP;SUITE 500

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; PL; PT; RO; RS; SE; SI; SK; TR; AE; AG; AM; AU; AZ; BB; BF; BH; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SM; SN; SV; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW



69. Family 43638206 (KR20090088757 A)

[View in PatBase](#)

Title

[EN] DATA PROCESSING, ANALYSIS METHOD OF GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES

Abstract

[EN] A method for treating and analyzing gene expression data is provided to totally analyze data in data base and identify standard expression gene. A method for selecting candidate standard expression gene comprises: a step of digitalizing the expression amount of gene in EST, SAGE and microarray data set; a step of selecting a gene which is expressed in different tissues with zero rate and expression amount of gene; In the digitalization of gene expression amount, the math equation 1 and 2 is used. The math equation 1 is EST gene expression amount = (the number of EST of specific gene in specific library/the number of total EST in specific library) X 1000000, and math equation 2 is SAGE gene expression amount = (the number of tag of specific gene in specific library / the number of total tag in specific library) X 1000000.

International Class: C12Q1/68

Cooperative Patent Class: A41D1/04; A41D13/0125; A41D27/20

Family Information

Patent Number	Publication Date	Application Number	Application Date
KR20090088757 A	20090820	KR20080014214	20080215

Priority Numbers: KR20080014214 [20080215]

Probable Patent Assignee: SEOUL NAT UNIV IND FOUNDATION

Assignees: SEOUL NAT UNIV IND FOUNDATION; SEOUL NATIONAL UNIV IND FOUNDATION

Non Std Assignees: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION

Inventors: OH EN SEL; SHIN YOUNG KEE; KWON MI JEONG; IN YONG HO; KOH SANG SEOK



70. Family 32120814 (US2005208472 AA)

[View in PatBase](#)

Title
[EN] MODULATORS OF ANGIOGENESIS

Abstract
[EN] The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.

International Class: A61K31/7105; A61K39/395; C12Q1/00; C12Q1/32; C12Q1/37; C12Q1/48; G01N33/53; G01N33/566; G01N33/574; C12N15/06; C12N15/52; C12N5/10; C12N9/14; G01N33/573

Cooperative Patent Class: C12Q1/32; C12Q1/37; C12Q1/485; G01N2333/515; G01N33/566

US Class: 435/18; 435/195; 435/23; 435/23S; 435/362; 435/4; 435/4P; 435/69.2; 435/7.1; 435/7.21

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP1721158 A2	20061115	EP20050705695	20050113
EP1721158 A4	20080730	EP20050705695	20050113
US2005208472 AA	20050922	US20050036643	20050113
US7527936 BB	20090505	US20050036643	20050113
WO05069855 A2	20050804	WO2005US01194	20050113
WO05069855 A3	20050922	WO2005US01194	20050113

Priority Numbers: US20040536310P [20040113]; WO2005US01194 [20050113]; US20050036643 [20050113]

Probable Patent Assignee: RIGEL PHARMACEUTICALS INC

Assignees: RIGEL PHARMACEUTICALS INC; LORENS JAMES; XU WEIDUAN; HOLLAND SACHA J


Non Std Assignees: RIGEL PHARMACEUTICALS INCORPORATED; MIDCAP FINANCIAL TRUST

Inventors: LORENS JAMES; XU WEIDUAN; HOLLAND SACHA J

Non Std Inventors: HOLLAND SACHA

Agent(s): TOWNSEND AND TOWNSEND AND CREW LLP; KLARQUIST SPARKMAN LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; NL; PL; PT; RO; SE; SI; SK; TR; YU; AE; AG; AM; AU; AZ; BB; BF; BJ; BR; BW; BY; BZ; CA; CF; CG; CI; CM; CN; CO; CR; CU; DM; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GW; ID; IL; IN; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; MA; MD; MG; ML; MN; MR; MW; MX; MZ; NA; NE; NI; NO; NZ; OM; PG; PH; RU; SC; SD; SG; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; SM



71. Family 41670356 (US2008081791 AA)

[View in PatBase](#)

Title

[EN] METHODS OF USING COMBINATIONS OF SIRNAS FOR TREATING A DISEASE OR A DISORDER, AND FOR ENHANCING SIRNA EFFICACY IN RNAI

Abstract

[EN] The present invention provides methods for treating diseases or disorders, and methods for enhancing siRNA efficacy in RNAi, including administering to a subject or a biological system one or more siRNAs capable of down regulating the expression of one or more target genes and one or more siRNAs capable of down regulating the expression of one or more negative regulators of RNAi. The present invention also provides compositions including one or more siRNAs, or precursors thereof, capable of down regulating the expression of one or more target genes and comprising one or more siRNAs, or precursors thereof, capable of down regulating the expression of one or more negative regulators of RNAi.

International Class: A61K31/7042; A61K31/7052; A61P35/00; A61P43/00; C07H21/00; C07H21/02; C12N15/00

Cooperative Patent Class: A61P35/00; A61P43/00; C12N15/111; C12N15/113; C12N15/1131; C12N15/1135; C12N2310/111; C12N2310/14; C12N2310/53; C12N2320/50

US Class: 435/455; 514/44; 514/44A; 536/23.1

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2008081791 AA	20080403	US20060481879	20060706

Priority Numbers: US20060481879 [20060706]


Probable Patent Assignee: SHANGHAI HENGDA SCIENCES AND TECHNOLOGY DEVELOPMENT CO LTD

Assignees: HONG JIE; HUANG WEIDA; QIAN ZHIKANG

Non Std Assignees: SHANGHAI HENGDA SCIENCES AND TECHNOLOGY DEVELOPMENT CO LTD; SHANGHAI HENGDA SCIENCES AND TECHNOLOGY; SHANGHAI HENGDA SCIENCES AND TECHNOLOGY DEVELOPMEN

Inventors: HONG JIE; HUANG WEIDA; QIAN ZHIKANG

Agent(s): FISH AND RICHARDSON PC



72. Family 34173969 (US2007026393 AA)

[View in PatBase](#)

Extended Family Number: 30199944

Title
[EN] DETECTION OF VARIATIONS IN THE DNA METHYLATION PROFILE

Abstract

[EN] The invention describes a set of oligonucleotides as probes for the detection of relevant variations of DNA methylation in a target group of genes, the use thereof for the detection of gene variants with respect to DNA methylation, a medical device which uses a set of oligonucleotides, a method for investigating the methylation state of an individual as well as a method for creating a model for evaluating the probability of occurrence of a health problem of an individual. Such disorders can be: undesired drug interactions cancer diseases CNS malfunctions, damage or disease symptoms of aggression or behavioral disturbances clinical, psychological and social consequences of brain lesions psychotic disturbances and personality disorders dementia and/or associated syndromes cardiovascular disorder, malfunction and damage malfunction, damage or disorder of the gastrointestinal tract malfunction, damage or disorder of the respiratory system lesion, inflammation, infection, immunity and/or convalescence malfunction, damage or disease of the body as an abnormality in the development process malfunction, damage or disorder of the skin, the muscles, the connective tissue or the bones endocrine and metabolic malfunction, damage or disorder headaches or sexual malfunction.

International Class: A61K31/711; A61K48/00; A61P11/06; A61P13/12; A61P29/00; A61P35/00; A61P7/04; A61P9/10; B01J19/00; C07K14/435; C07K14/46; C07K14/47; C07K14/82; C12M1/00; C12N15/09; C12Q1/48; C12Q1/68; G01N27/62; G01N33/483; G01N33/53; G01N33/566; G01N37/00; A61P11/00; A61P13/00; A61P7/00; A61P9/00; C07H21/00; C07H21/04; C12Q1/6883; C12M1/34; C12P19/34; G01N33/58

Cooperative Patent Class: A61P11/06; A61P13/12; A61P29/00; A61P35/00; A61P7/04; A61P9/10; C07K14/4703; C07K14/82; C12Q1/6883; C12Q1/6886; C12Q2600/154; C12Q2600/156; C12Q2523/125

US Class: 435/6; 435/6.12; 435/6.120P; 435/6.13; 435/6.130S; 435/6P; 435/91.2; 435/91.200S; 536/24.3; 536/24.300S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2001276330 AA	20011023	AU20010276330	20010406
AU2001276330 BB	20060831	AU20010276330	20010406
DE60126593 D1	20070329	DE20016026593T	20010406
DE60126593 T2	20071031	DE20016026593T	20010406
US2007026393 AA	20070201	US20030240970	20030711
US2008026396 AA	20080131	US20070835336	20070807

Priority Numbers: DE20001019058 [20000406]; DE20001043826 [20000901]; DE20001032529 [20000630]; DE20001019173 [20000407]; WO2001EP03969 [20010406]; WO2001DE01486 [20010406]; US20070835336 [20070807]; US20020311507 [20021216]; WO2001EP07538 [20010702]


Probable Patent Assignee: EPIGENOMICS AG

Assignees: EPIGENOMICS AG; PIEPENBROCK CHRISTIAN; OLEK ALEXANDER; BERLIN KURT

Inventors: PIEPENBROCK CHRISTIAN; OLEK ALEXANDER; BERLIN KURT

Non Std Inventors: ALEXANDER OLEK; CHRISTIAN PIEPENBROCK; KURT BERLIN

Agent(s): GRIFFITH HACK; WATERMARK INTELLECTUAL PROPERTY PTY LTD; WATERMARK PATENT AND TRADE MARKS ATTORNEYS; KRIEGSMAN AND KRIEGSMAN; DAVIS WRIGHT TREMAINE LLP SEATTLE



[View in PatBase](#)

[EN] MAT2AS AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE

[EN] Human MAT2A genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAT2A are provided.

International Class: C12N; C12Q1/00; C12Q1/02; C12Q1/48; G01N33/53; G01N33/573; G01N33/574

Cooperative Patent Class: C12Q1/48; G01N2500/00; G01N33/573; G01N33/574



Patent Number	Publication Date	Application Number	Application Date
AU2003303094 AA	20040813	AU20030303094	20031229
AU2003303094 AH	20040813	AU20030303094	20031229
WO04065542 A2	20040805	WO2003US41439	20031229
WO04065542 A3	20041229	WO2003US41439	20031229

Priority Numbers: US20020437162P [20021230]; WO2003US41439 [20031229]

Probable Patent Assignee: EXELIXIS INC

Assignees: EXELIXIS INC; FRANCIS LANG HELEN; FRIEDMAN LORI; PLOWMAN GREGORY D; BELVIN MARCIA; LICKTEIG KIM

Inventors: FRANCIS LANG HELEN; LICKTEIG KIM; FRIEDMAN LORI; BELVIN MARCIA; PLOWMAN GREGORY D

Non Std Inventors: GREGORY D PLOWMAN; KIM LICKTEIG; HELEN FRANCIS LANG; MARCIA BELVIN; LORI FRIEDMAN

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GW; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MC; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NE; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; SN; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

74. Family 20682968 (US2003198970 AA)

[View in PatBase](#)

Title
[EN] GENOSTICS

Abstract

[EN] People vary enormously in their response to disease and the also in their response to therapeutic interventions aimed at ameliorating the disease process and progression. However, the provision of medical care and medical management is centered around observations and protocols developed in clinical trials on groups or cohorts of patients. This group data is used to derive a standardised method of treatment which is subsequently applied on an individual basis. There is considerable evidence that a significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiological response. In order to bring about the integration of genomics into medical practice and enable design and building of a technology platform which will enable the everyday practice of molecular medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiological states of interest. According to the invention, the number of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide critical clinical information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies which comprises of the identification of the core group of genes and their sequence variants required to provide a broad base of clinical prognostic information--'genostics'. The "Genostic™" profiling of patients and persons will radically enhance the ability of clinicians, healthcare professionals and other parties to plan and manage healthcare provision and the targeting of appropriate healthcare resources to those deemed most in need. The use of our invention could also lead to a host of new applications for such profiling technologies, such as identification of persons with particular work or environment related risk, selection of applicants for employment, training or specific opportunities or for the enhancing the planning and organisation of health services, education services and social services.

International Class: C07K16/18; C12M1/00; C12N15/09; C12Q1/68; C07H21/04

Cooperative Patent Class: C07K16/18; C12Q1/6827; C12Q1/6883; C12Q1/6886; C12Q2600/106

US Class: 435/6; 435/6.14; 435/6.140P; 435/6P; 536/24.3; 536/24.300S

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU199941586 A1	19991230	AU19990041586	19990604
AU766544 B2	20031016	AU19990041586	19990604
CA2330929 AA	20001205	CA19992330929	19990604
EP1084273 A1	20010321	EP19990925207	19990604
GB200118013 A0	20010919	GB20010018013	20010724
GB2339200 A1	20000119	GB19990012914	19990604
GB2339200 B2	20010912	GB19990012914	19990604
GB9812098 A0	19980805	GB19980012098	19980606
GB9828289 A0	19990217	GB19980028289	19981223
GB9912914 A0	19990804	GB19990012914	19990604
JP2003528564 T2	20030930	JP20000553616T	19990604
US2003198970 AA	20031023	US20020206568	20020729
WO9964626 A2	19991216	WO1999GB01779	19990604
WO9964626 C1	20000420	WO1999GB01779	19990604

Priority Numbers: GB19980012098 [19980606]; GB19980028289 [19981223]; WO1999GB01779 [19990604]; US20020206568 [20020729]; US19990325123 [19990603]

Probable Patent Assignee: GENOSTIC PHARMA LTD


Assignees: GENOSTIC PHARMA LTD; ROBERTS GARETH WYN

Non Std Assignees: GENOSTIC PHARMA LIMITED

Inventors: ROBERTS GARETH WYN

Non Std Inventors: GARETH WYN ROBERTS

Agent(s): SHELSTON IP; SHELSTON IP PTY LTD; SPRUSON AND FERGUSON; SIM AND MCBURNEY



Designated States: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; AE; AL; AM; AU; AZ; BA; BB; BF; BG; BJ; BR; BY; CA; CF; CG; CI; CM; CN; CU; CZ; EE; GA; GD; GE; GH; GM; GN; GW; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MD; MG; MK; ML; MN; MR; MW; MX; NE; NO; NZ; PL; RO; RU; SD; SG; SI; SK; SL; SN; SZ; TD; TG; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW

75. Family 33496660 (EP1278892 A1)

[View in PatBase](#)

Extended Family Number: 30199944

Title

[EN] DETECTION OF VARIATIONS IN THE DNA METHYLATION PROFILE

Abstract

[EN] The invention describes a set of oligonucleotides as probes for the detection of relevant variations of DNA methylation in a target group of genes, the use thereof for the detection of gene variants with respect to DNA methylation, a medical device which uses a set of oligonucleotides, a method for investigating the methylation state of an individual as well as a method for creating a model for evaluating the probability of occurrence of a health problem of an individual. Such disorders can be: undesired drug interactions cancer diseases CNS malfunctions, damage or disease symptoms of aggression or behavioral disturbances clinical, psychological and social consequences of brain lesions psychotic disturbances and personality disorders dementia and/or associated syndromes cardiovascular disorder, malfunction and damage malfunction, damage or disorder of the gastrointestinal tract malfunction, damage or disorder of the respiratory system lesion, inflammation, infection, immunity and/or convalescence malfunction, damage or disease of the body as an abnormality in the development process malfunction, damage or disorder of the skin, the muscles, the connective tissue or the bones endocrine and metabolic malfunction, damage or disorder headaches or sexual malfunction.

International Class: C07K14/47; C07K14/82; C12Q1/68; C12Q1/6883; C07K14/435

Cooperative Patent Class: C07K14/4703; C07K14/82; C12Q1/6883; C12Q2600/154

Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2001273840 AA	20011023	AU20010273840	20010406
AU200173840 A1	20011023	AU20010073840	20010406
AU200173840 A5	20011023	AU20010073840	20010406
EP1278892 A1	20030129	EP20010940158	20010406

Priority Numbers: DE20001019058 [20000406]; WO2001DE01486 [20010406]; WO2001DE001486 [20010406]

Probable Patent Assignee: EPIGENOMICS AG

Assignees: EPIGENOMICS AG

Inventors: PIEPENBROCK CHRISTIAN; OLEK ALEXANDER; BERLIN KURT

Non Std Inventors: ALEXANDER OLEK; CHRISTIAN PIEPENBROCK; KURT BERLIN

Agent(s): DAVIES COLLISON CAVE; DAVIES COLLISON CAVE PTY LTD


Designated States: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR

76. Family 22807509 (US2870818 A)

[View in PatBase](#)

Title
[EN] RESILIENT ROLL APPARATUS FOR WORKING TENUOUS MATERIAL

Abstract
[EN] (Claim 1) 1. Apparatus for imparting 11 predetermined set to sheet material of varying thickness, comprising a p1n~ rality of rolls providing a tortuous pass through which the material travels, certain of said rolls engaging one side of the material and certain other of said rolls engaging the other side of the material and said rolls having deformable, resilient peripheral Working surfaces in pressure contact with the material traveling through said pass to bend the material in one direction about the radii of certain of said rolls and in the other direction about the radii of certain other of said rolls to flex the material beyond its elastic limit, said pressure cunlact between the material and said rolls varying in accordance with material thickness and eiTecting temporary deformation of the peripheries of said rolls to respective arcuate shapes having radii larger than the initial, undeformed radii cf said rolls, the radii to which the peripheries of said rolls are deformed varying in accordance with said pressure contact and automatically increasing with an increase in material thickness to reduce the amount that the mat2a~ rial is bent and automatically decreasing with a decrease in material thickness to increase the amount that the material is bent to automatically impart said predetermined set to the material despite variations in thickness thereof.



International Class: B21D1/00; B21D1/02; B21C19/00

Cooperative Patent Class: B21D1/02

US Class: 72/164

Family Information

Patent Number	Publication Date	Application Number	Application Date
US2870818 A	19590127	US19540461090	19541008

Priority Numbers: US19540461090 [19541008]

Probable Patent Assignee: HERR EQUIPMENT CORP

Assignees: HERR EQUIPMENT CORP

Inventors: HERR RICHARD F